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ABSTRACT 
IL-34 is a challenging cytokine sharing functional similarities with M-CSF through M-
CSFR activation. It also plays a singular role that has recently been explained in the brain, 
through a ฀b฀i฀n฀d฀i฀n฀g฀ ฀t฀o฀ ฀t฀h฀e฀ ฀r฀e฀c฀e฀p฀t฀o฀r฀ ฀p฀r฀o฀t฀e฀i฀n฀ ฀t฀y฀r฀o฀s฀i฀n฀e฀ ฀p฀h฀o฀s฀p฀h฀a฀t฀a฀s฀e฀ ฀R฀P฀T฀Pȕ฀/ȗ฀.฀ The aim of this paper 
was to look for alternative binding of IL-34 on other cell types. Myeloid cells (HL-60, U-937, 
THP-1) were used as cells intrinsically expressing M-CSFR, and M-CSFR was expressed in 
TF-1 and HEK293 cells. IL-34 binding was studied by Scatchard and binding inhibition 
assays, using 125I-radiolabelled cytokines, and surface plasmon resonance. M-CSFR activation 
was analysed by Western blot after glycosaminoglycans abrasion, syndecan-1 overexpression 
or repression and addition of a blocking anti-syndecan antibody. M-CSF and IL-34 induced 
different patterns of M-CSFR phosphorylations, suggesting the existence of alternative 
binding for IL-34. Binding experiments and chondroitinase treatment confirmed low affinity 
binding to chondroitin sulfate chains on cells lacking both M-฀C฀S฀F฀R฀ ฀a฀n฀d฀ ฀R฀P฀T฀Pȕ฀/ȗ. Amongst 
the proteoglycans with chondroitin sulphate chains, syndecan-1 was able to modulate the IL-
34-induced M-CSFR signalling pathways. Interestingly, IL-34 induced the migration of 
syndcean-1 expressing cells. Indeed, IL-34 significantly increased the migration of THP-1 and 
M2a macrophages that was inhibited by addition of a blocking anti-syndecan-1 antibody.  
This paper provides evidence of alternative binding of IL-34 to chondroitin sulfates and 
syndecan-1 at the cell surface that modulates M-CSFR activation. In addition, IL-34-induced 
myeloid cell migration is a synedcan-1 dependent mechanism. 
 
 
 
 
 3 
1. INTRODUCTION 
The discovery of interleukin-34 (IL-34) in 2008 upset the functional biological concepts 
that had been admitted for many years between Macrophage Colony Stimulating Factor (M-
CSF) and its receptor, the M-CSF receptor (M-CSFR) >1,2@. Like M-CSF, IL-34 promotes the 
survival and proliferation of monocytes, as well as their differentiation into macrophages >3@. 
Macrophages induced by IL-34 have phenotypes and functions that are similar to those 
differentiated by M-CSF, as both cytokines polarize these macrophages into 
immunosuppressive macrophages M2 >4@. In addition, and in association with the Receptor 
Activator of Nuclear Factor Kappa-B Ligand (RANKL), IL-34 can replace M-CSF to induce 
osteoclast formation by stimulating the proliferation and adhesion of osteoclast precursors >5@. 
The cytokine also overlaps with the roles played by M-CSF in inflammation in degenerative 
bone diseases such as rheumatoid arthritis >6@ and periodontal inflammation >7@. All these 
effects are mediated by a cell-surface tyrosine kinase activity receptor, M-CSFR, encoded by 
the proto-oncogene c-fms, and also called c-fms, CD115 or CSF-1R >8@. The homodimeric 
cytokines M-CSF or IL-34 bind in a close way to the extracellular domain of M-CSFR, but 
with a different binding mode >9,10@, leading to receptor dimerization and differential auto-
phosphorylation on its eight tyrosine residues >11@. M-CSF/M-CSFR and IL-34/M-CSFR 
crystals have quite a similar shape, except a higher stability for the IL-34/M-CSFR complex 
>12@. Chihara et al. showed some differences in the kinetics of M-CSFR phosphorylations and 
in the nature and intensity of phosphorylated tyrosine residues after M-CSF or IL-34 binding, 
which partly explains their ability to differentially activate the monocyte/macrophage lineage 
>13@. 
MCSF-R knockout mice >14@ exhibit a similar but more pronounced phenotype than 
op/op mice >15,16@ characterized by a more severe osteopetrosis and reduction of tissue 
macrophages. This osbservation suggested the existence of another ligand for the M-CSFR, 
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and IL-34 was a perfect candidat. Although IL-34 expression under the promoter of the M-
CSF gene rescues the phenotype of op/op mice, the cytokine also plays singular roles during 
brain development >17@. Microglia and Langerhans cells effectively decrease dramatically in 
IL-34 knockout mice, as in M-CSFR deficient mice, while monocytes, lymphoid tissue 
macrophages and dendritic cells are not affected. Besides, op/op mice show quite a 
conventional development of these cells >18-20@. These results identify specific IL-34 activity 
during embryogenesis and tissue homeostasis, and make it possible to better understand the 
tissue distribution and independent activity of IL-34 >21@. 
IL-34 is highly expressed in both post-natal and adult brains, whereas M-CSFR 
expression, which is maximal in early development, dramatically decreases in adult brains 
>22@. High expression of IL-34 despite an almost undetectable expression of its receptor 
suggests the existence of other receptors for the cytokine. In spite of overlapping and 
complementary activities between M-CSF and IL-34 through M-฀C฀S฀F฀R฀ ฀a฀c฀t฀i฀v฀a฀t฀i฀o฀n฀,฀ ฀t฀h฀e฀ ฀“฀M-
฀C฀S฀F฀ ฀t฀w฀i฀n฀”฀ may also exert specific functions independently of this receptor. The present study 
thus investigates a new binding mode for IL-34 that may modulate the bioavailability and/or 
activities of this cytokine. This paper provides evidence of syndecan-1 as a new molecular 
actor in the M-CSF/IL-34/M-CSFR triad and proposes one explanation for the differential 
activation of the M-CSFR observed after M-CSF and IL-34 stimulation. 
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2. MATERIAL AND METHODS 
All experiments described in the manuscript were repeated at least three times in independent 
experiments and representative experiments are shown. 
 
2.1. Reagents 
Recombinant human Macrophage-Colony Stimulating Factor (M-CSF), human interleukin-34 
(IL-34), human M-CSF Receptor (M-CSFR), mouse IgG1 (control isotype) and antibody anti-
human M-CSFR ฀w฀e฀r฀e฀ ฀o฀b฀t฀a฀i฀n฀e฀d฀ ฀f฀r฀o฀ ฀ ฀R฀ ฀ ฀ ฀S฀y฀s฀t฀e฀ ฀s฀ ฀ ฀ ฀b฀i฀n฀g฀d฀o฀n฀,฀ U฀ .  ฀ ฀i฀a c฀ o n e฀   e s a n c ฀on, 
France) kindly provided the murine B-B4 anti-syndecan 1 (CD138) IgG1 monoclonal 
antibody.  Antibodies directed against human CD14, human CD200R and human CD86 were 
purchased from Biolegend (Saint Quentin en Yvelines, France). Antibodies directed against 
human P-MCSFR, P-Erk1/2, P-mTor,  P-Akt and the total form of proteins were purchased 
from Cell Signalling (Ozyme, Saint Quentin Yvelines, France). Anti-ȕ actin and total 
phosphorylated tyrosine antibodies were respectively provided by Sigma-Aldrich (Saint 
Quentin Fallavier, France) and Millipore (Molsheim, France). Anti-Receptor Protein Tyrosine 
Phosphatase ฀ ฀R฀P฀T฀Pȕ฀/ȗ฀, C-19 clone) and HRP-conjugated secondary antibodies were obtained 
from Santa-Cruz (CliniSciences, Nanterre, France). Chondroitin sulfate salts from shark 
cartilage, heparin, heparan sulfate salts and chondroitinases A, B, C were purchased from 
Sigma-Aldrich (Saint Quentin Fallavier, France).  
 
2.2. Cell cultures 
The cell lines used in the present study were purchased from the American Tissue Cell 
Collection (ATCC, Molsheim, France). HEK293 (HEK), osteosarcoma MNNG/HOS 
(ATCC® Number: CRL-1547฀™) (HOS) were cultured in DMEM (Dulbecco's Modified 
Eagle's Medium, Lonza, Levallois-Perret, France) supplemented with 10% foetal bovine 
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serum (FBS; HyclonePerbio, Bezons, France) and 2 mmol/L of L-glutamine. HL-60, U937, 
THP-1 and TF-1cell lines were maintained in RPMI (Roswell Park Memorial Institute, 
Lonza) supplemented with 10% FBS. In addition, TF-1 cells were cultured in the presence of 
3 ng/mL of G-MCSF according to ATCC recommendations. The human U251 glioblastoma 
cell line was kindly provided by Dr Mylène Dorvillius (ATLAB Pharma, Nantes, France) and 
cultured in DMEM supplemented with 10 % FBS. 
 
2.3. Cloning of the human M-CSFR gene and cell transfection 
The human M-CSFR gene (NM_005211.3) was cloned in a pCDNA3.3 TOPO TA vector 
(Life Technologies, Villebon sur Yvette, France) from the cDNA from a healthy donor 
CD14+. CD14+ cells were initially isolated from human peripheral blood donors provided by 
the French blood bank institute (Etablissement Français du Sang, Nantes, France, 
authorization number: NTS 2000-24), by using MACS microbeads (MiltenyiBiotec, 
Germany) as previously described >5@. The RT-PCR product was obtained using the following 
primer sequences: Forward ฀5฀’-CACCATGGGCCCAGGAGTTCTGCTGCT-฀γ฀’ and Reverse 
฀5฀’-AACTCCTCAGCAGAACTGATAGTTGTTGGGCTGCA-฀γ฀’, and fully sequenced to 
check for the absence of functional mutations based on the sequences already published in the 
data bases. 
 Embryonic HEK293 cells and osteosarcoma HOS cells were transfected as described 
below with the pCDNA3 empty plasmid or the pCDNA3 plasmid containing the M-CSFR 
gene. To obtain a polyclonal population expressing the membrane M-CSFR, 5x106 cells were 
then stained with phycoerythrin (PE) conjugated antibodies directed against the M-CSFR and 
sorted out on a FACSAria III (Beckman Coulter, Villepinte, France). The cells expressing the 
M-CSFR were named respectively HEK M-CSFR and HOS M-CSFR. The cells transfected 
with the empty pCDNA3 vector were called HEK Mock and HOS Mock. Erythroblastic TF-1 
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cells were transfected using an Amaxa® Cell Line Nucleofector® Kit by Lonza. Cell sorting 
was also carried out to isolate M-CSFR expressing cells (TF-1 M-CSFR).  
 
2.4. RNA isolation and real-time PCR 
Total RNA was extracted using NucleoSpin®RNAII (Macherey Nagel, Duren, Germany) 
with one stage of DNase I treatment (25 units, 15 min) to prevent genomic contamination. 1 
ȝ฀g฀ ฀o฀f฀ ฀t฀o฀t฀a฀ ฀ ฀R฀N฀ ฀ ฀w฀a฀s฀ ฀u฀s฀e฀d฀ ฀f฀o฀r฀ ฀f฀i฀r฀s฀t฀ ฀s฀t฀r฀a฀n฀d฀ ฀c฀ ฀N฀  synthesis using the ThermoScript RT-PCR 
System (Invitrogen). Real-time PCR was performed on 20 ng of reverse transcribed total 
RNA (cDNA), 300 nM of primers and 2x SYBR Green Supermix (Biorad, Marnes-la-
Coquette, France). The analysis was performed according to the method described by 
Vandesompele et al. [23] using human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
as the invariant control. Standard curves were obtained using decreasing quantities of cDNA 
from the U251 cell line to validate the ฀R฀P฀T฀Pȕ฀/ȗ฀ ฀p฀r฀i฀ ฀e฀r฀s฀ ฀a฀c฀c฀o฀r฀d฀i฀n฀g฀ to the MIQE guidelines 
>24@. The sense and antisense primers used were: ฀R฀P฀T฀Pȕ฀/ȗ Forward: ฀5฀’-
GCAGAGCTGTACTGTTGACTT-3฀’, R฀e฀v฀e฀r฀s฀e฀:฀ ฀5฀’-TGTGCTAGCTTAACCCTGCT-฀γ฀’฀; 
GAPDH Forward: ฀5฀’-TGGGTGTGAACCATGAGAAGTATG-฀γ฀’, Reverse: ฀5฀’-
GGTGCAGGAGGCATTGCT-฀γ฀’. 
 
2.5. M-CSF and IL-34 binding assays  
M-CSF and IL-34 were radio-labelled with iodine-125 (125I) (which has specific radioactivity 
of around 2,000 cpm/fmol) using the chloramine T method, as described by Tejedor and 
Ballesta >25@ and Godard et al >26@. To determine the ability to bind to the cells of both 
cytokines, 1x106 cells were incubated with increasing concentrations of iodinated M-CSF or 
IL-34 (up to 1nM) for 1 h at 4°C. Non-specific binding was determined in the presence of 
100-fold excess of the corresponding unlabelled cytokine. Specific binding was subsequently 
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obtained by subtraction of this non-specific binding from the total binding signal. Regression 
analysis of the binding data was carried out using a one-site equilibrium binding equation 
(Graphit; Erithacus Software, Staines, U.K.) and data were plotted in the Scatchard coordinate 
system. Cross competition binding curves were obtained by adding simultaneously to the cells 
increasing amounts of a competitor cytokine together with a fixed, non-saturable 
concentration of a labelled cytokine. The inhibition curves obtained were analysed with an 
equation for competitive inhibition between two ligands for a common binding site. Curve 
fittings were performed using the Graphit data analysis programme. 
 
2.6. Surface Plasmon Resonance (SPR) assays 
The SPR experiments were carried out on a BIAcore 2000 biosensor (BIAcore, Uppsala, 
Sweden). Recombinant human IL-34 (5µg/mL, in 5 mM maleate buffer pH=6.2) was 
covalently linked to the dextran matrix of a CM5 sensor chip (BIAcore, Uppsala, Sweden), 
previously activated with an ethyl (dimethylaminopropyl) carbodiimide/ N-
hydroxysuccinimide (EDC/NHS) mixture. Immobilisation levels in the 1300 RU range were 
then obtained. Residual active groups were inactivated by injection of ethanolamine 1M 
pH=8.5 for 10 min. The binding of decreasing concentrations of chondroitin sulfate salts, 
heparin or heparan sulfate salts was monitored, from 100 µg/mL and with a serial dilution of 
1:3. Concentrations up to 500 µg/mL were assessed for the heparin and heparan sulfate. The 
flow rate was around 30 µL/min, and the chip was regenerated with 20 mM NaOH between 
each cycle. The resulting sensorgrams were fitted using BiaEval 4.1 software.  
Cell binding experiments were carried out in the SPRiplex II. The SPRi biochip-CH 
(H0550) was activated with an EDC/NHS mixture, and 200 µg/mL IL-34 was spotted on it 
with a 500µM tip for 30 min. The protein binding capacity of the IL-34 was controlled by 
injections of 1 and 2 µg/mL of recombinant human M-CSFR on the chip after each 
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regeneration cycle performed with 10mM glycine pH=1.5. HEK Mock cells (2x105 cells/mL) 
were then injected on to the chip at 20 µL/min for 10 min. 
 
2.7. Flow-cytometry experiments 
Membrane expression of the M-CSFR, syndecan-1, CD14, CD220R, CD86 were assessed 
with flow cytometry (Cytomics FC500; Beckman Coulter). Cells were incubated with PE-
conjugated anti-human M-CSFR antibody or mouse IgG1 as the control for 30 min. For 
syndecan-1 expression, the cells were first incubated for 90 min at 4°C with the anti-
syndecan-1 B-B4, before incubation with the PE-conjugated secondary antibody for 60 min. 
Similar method was used to analyse CD14, CD220R and CD86 expression. M-CSFR and 
syndecan-1 expressions were analysed using the CXP Analysis software 2.2 (Beckman 
Coulter).  
 
2.8. Western Blot Analysis 
The cells were collected in a RIPA buffer (10 mM Tris pH8, 1 mM EDTA, 150 mM NaCl, 
1% NP40, 0.1% SDS containing a cocktail of protease and phosphatase inhibitors: 1 mM 
sodium orthovanadate (Na2VO4), 1 mM phenylmethylsulforyl fluoride (PMSF), 10 mM 
sodium fluoride (NaF), 10 mM N-฀e฀t฀h฀y฀ ฀ ฀a฀ ฀e฀i฀ ฀i฀d฀e฀ ฀ ฀N฀E฀M฀ ฀,฀ ฀β฀ ȝ฀g฀/฀ ฀ ฀ ฀ ฀e฀u฀p฀e฀p฀t฀i฀n฀ ฀a฀n฀d฀ ฀1฀ ȝ฀g฀/฀ ฀ ฀ 
pepstatine). The protein concentration was determined using a BCA (bicinchoninic acid) 
prote฀i฀n฀ ฀a฀s฀s฀a฀y฀ ฀ ฀S฀i฀g฀ ฀a฀ ฀ ฀ ฀d฀r฀i฀c฀h฀ ฀.฀ ฀δ฀0฀ ȝ฀g฀ ฀o฀f฀ ฀t฀o฀t฀a฀ ฀ ฀p฀r฀o฀t฀e฀i฀n฀ ฀e฀x฀t฀r฀a฀c฀t฀s฀ ฀w฀e฀r฀e฀ ฀p฀r฀e฀p a r e d  ฀i฀n฀ ฀a฀ ฀L฀a฀e฀ ฀ ฀i  
buffer (62.5 mM Tris฀–HCl, pH 6.8, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.001% 
bromophenol blue) and then separated by SDS-polyacrylamide gel electrophoresis. After 
electrophoretic transfer, the immobilon-P membranes (Millipore, Molsheim, France) were 
blotted with the antibodies referenced in the reagents section. The membranes were then 
probed with secondary antibodies coupled with horseradish peroxidase. Antibody binding was 
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visualised with a Pierce enhanced chemiluminescence (ECL) kit (ThermoSientific, Illkirch, 
France). The luminescence detected with a Charge Couple Device (CCD) camera was 
quantified using the GeneTools programme (Syngene, Cambridge, United Kingdom). 
 
2.9. siRNA gene silencer 
The syndecan-1 gene expression was knocked down using specific human syndecan-1 siRNA 
(Ambion, France) and the INTERFERinTM transfection reagent (Polyplus transfection, 
France). 700 x 103 HEK M-CSFR cells per well were seeded in a 6-well plate 1 day before 
transfection. In each well 50 nm siRNA (Syndecan-1 siRNA : ref#s12634 ; Ambion® 
Silencer® Negative Control #1 : ref#AM4611) duplexes diluted in serum-free medium were 
฀i฀n฀c฀u฀b฀a฀t฀e฀d฀ ฀w฀i฀t฀h฀ ฀β฀ ȝ฀ ฀ ฀o฀f฀ ฀I฀N฀T฀E฀R฀F฀E฀R฀i฀nTM for 30 min at room temperature. The expression of 
membrane syndecan-1 was measured by flow cytometry. 48 h after the transfection, 50 ng/mL 
of IL-34 (5 min, 37°C) were added to the cells and M-CSFR activation was determined by 
Western blot as previously described. 
 
2.10. M2a macrophage differentiation and cell migration assays 
CD14+ monocytes were isolated from peripheral blood of 3 healthy donors as previously 
described in paragraph 2.3. For M2a macrophage differentiation, CD14+ cells were cultured in 
RPMI (Roswell Park Memorial Institute medium, Lonza) supplemented with 1% Human 
Serum (Invitrogen), 1% penicillin/streptomycin, 50 ng/mL of IL-4 (R&D System) for 5 days. 
Half volume of the medium was renewed at day 2. After the differentiation culture period, 
M2a adherent cells were collected by gentle scraping. Their phenotype was analysed by flow 
cytometry (CD14low, CD220R+, CD86+) before use in migration assays. 2x105 M2a 
macrophages or 5x10
5 
THP-1 were pre-treated for 30 min at 37°C with a blocking anti 
syndecan-1 antibody (SDC-1 Ab, B-B4) or the corresponding isotype (IgG1 Ab). Cell 
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migration was then assessed using a 8µm Boyden chamber (top well) in RPMI 1% FCS, with 
or without 100 ng/mL of IL-34 at the bottom well. Cells migrating at the bottom well were 
counted after 6 hours of culture. Each experiment was done in triplicate and repeated three 
times. 
 
2.11. Statistical analysis 
Results were analyzed using a Kruskal-฀W฀a฀ ฀ ฀i฀s฀ ฀t฀e฀s฀t฀ ฀w฀a฀s฀ ฀p฀e฀r฀f฀o฀r฀ ฀e฀d฀ ฀f฀o฀ ฀ ฀o฀w฀e฀d฀ ฀b฀y฀ ฀a฀ ฀ ฀u฀n฀n฀’฀s฀ ฀p฀o฀s฀t-
hoc between all conditions using GraphPad InStat v3.02 software. The results of the migration 
assays are given as a mean ± SD of three independent experiments done in triplicate. Results 
฀w฀e฀r฀e฀ ฀c฀o฀n฀s฀i฀d฀e฀r฀e฀d฀ ฀s฀i฀g฀n฀i฀f฀i฀c฀a฀n฀t฀ ฀a฀t฀ ฀p฀ ฀v฀a฀ ฀u฀e฀s฀ ฀≤฀ ฀0฀.฀0฀5฀. All Western blots were performed three or four 
times in independent experiments and a representative blot was changed in each figure. 
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3. RESULTS 
3.1. IL-34 and M-CSF induce differential activation of the M-CSFR  
We first analysed the membrane expression of M-CSFR in various human cells with flow 
cytometry. As expected, the HL-60, U937 and THP-1 myeloid cell lines intrinsically 
expressed this cytokine receptor, in contrast to the erythroblastic TF-1, epithelial HEK293 and 
HOS osteosarcoma cells which did not express the M-CSFR (Figure 1A). The lack of M-
CSFR expression by the TF-1, HEK and HOS cells was confirmed by quantitative PCR (data 
not shown). Marked expression of the M-CSFR at the cell membrane was observed in M-
CSFR transfected TF-1, HEK and HOS cells (Figure 1A).  
Based on these observations, we investigated the functionality of the receptor by 
studying the cell signalling induced by M-CSF and IL-34, the two identified ligands of the M-
CSFR (Figures 1B-E). In HEK M-CSFR cells, both cytokines induced in a dose- (data not 
shown) and time-dependent manner the tyrosine 546, 699, 708, 723 and 923 phosphorylation 
of the receptor฀’฀s intracellular chains with a peak at 5 min (Figure 1B). Similarly, M-CSF and 
IL-34 induced the phosphorylation of Erk1/2. Compared to M-CSF, IL-34 induced a weaker 
activation of the signalling pathway mediated by M-CSFR activation, at the same dose and 
time (Figure 1B). In the HOS M-CSFR cells, high doses of IL-34 (200 ng/mL) appeared more 
efficient at inducing the phosphorylation of the M-CSFR compared to M-CSF, unlike low 
doses of the cytokine (50 ng/mL) (Figure 1C). This higher activation of the M-CSFR by IL-34 
was also observed with 100 ng/mL of cytokine in the TF-1 M-CSFR cells as demonstrated by 
fast and huge phosphorylation levels of the M-CSFR (Figure 1D), data in agreement with 
Chihara et al. >13@. We then investigated M-CSFR activation in the THP-1 cells which 
intrinsically expressed the receptor chains (Figure 1E). Consistent with the findings obtained 
with the TF-1 M-CSFR cells, the M-CSFR and MAPK downstream signalling pathways were 
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more activated by IL-34 than by M-CSF (Figure 1E, Supplementary data 1A). Similar results 
were obtained in the U937 cells (Supplementary data 1B). Overall, these data revealed that 
IL-34 and M-CSF differentially activated the M-CSFR signalling pathway according to the 
cell type studied. 
 
3.2. IL-34 binds to HEK and HOS cells lacking the M-CSFR  
In light of the differential signalling pathway induced by IL-34 and M-CSF, binding assays 
using 125I-ligands were carried out on the different cell lines of interest. A saturation binding 
curve was obtained, which after Scatchard transformation, made it possible to estimate the 
affinity of IL-34 for the membrane M-CSFR. 125I-IL34 bound all cell lines studied with an 
equilibrium dissociation constant around 2 nM, 0.55 nM, 1 nM and 0.75 nM for U937, THP-
1, HEK M-CSFR and HOS M-CSFR cells respectively (Figure 2A-D). As expected, 125I-
MCSF bound to the HEK M-CSFR and HOS M-CSFR with a similarly high affinity (Kd = 
0.35 nM). These data demonstrated the capacity of IL-34 to bind with a high affinity to cell 
lines expressing the M-CSFR (Figure 2D).  
We next assessed the potency of recombinant IL-34 and/or M-CSF to compete with 
125I-IL34 binding to cell surface receptors (Figures 3A, B). The results demonstrated that cold 
IL-34 and M-CSF differentially competed with the 125I-IL34 binding sites expressed in the 
HEK M-CSFR, as revealed by the slope factor of the inhibition curves (0.8 and 2 for M-CSF 
and IL-34 respectively) (Figure 3A,B). Similar results were obtained with the HOS M-CSFR 
cells (data not shown). 125I-IL34 binding assays were then performed in HEK Mock cells 
transfected with the empty control vector that did not express the M-CSFR (Figure 1A, Figure 
3C). Surprisingly, specific 125I-IL34 specific binding sites were detected at the surface of the 
HEK Mock cells (Figure 3C,D). This binding was characterised by a lower affinity (Kd = 14.6 
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nM) than those observed in the HEK M-CSFR (Figure 2B). In contrast to 125I-IL34, 125I-M-
CSF did not bind to cells lacking the M-CSFR (Supplementary data 2). Complementary SPR 
experiments reinforced these results and confirmed the ability of the HEK Mock cells to bind 
to recombinant IL-34 spotted on a sensorchip, in contrast to recombinant M-CSF, as measured 
by the increasing percentage of reflectivity (Figure 3E). The results clearly demonstrated an 
additional binding mode for IL-34 independent of the M-CSFR.  
 
3.3. IL-34 binding to chondroitin sulfate chains modulates M-CSFR activation 
As IL-34 bound with a relatively low affinity to cells that did not express the M-CSFR (HEK 
Mock and HOS Mock), cell signalling was further investigated in these cells after stimulation 
with a high dose of IL-34 (200ng/mL). As shown in Supplementary data 3, the profile of the 
phosphorylated tyrosines was not modified after IL-34 stimulation (Supplementary data 3A) 
and no modulation of the different signalling pathways such as mTor, Akt, (Supplementary 
data 3B), ȕ-catenin, p38 and Erk1/2 (data not shown) was observed in the presence of IL-34. 
Consistent with the ability of IL-34 to bind to glycosaminoglycans >27@, we assessed the IL-
34 binding to chondroitin sulfate and heparin/heparan sulfate chains by SPR. The SPR 
sensorgrams revealed a low affinity binding of the various types of chondroitin sulfate to IL-
34, with a Kd of 132 nM, 775 nM and 16.1 nM for chondroitin sulfates A (Figure 4A), B 
(Figure 4B) and C (Figure 4C) respectively. On the contrary, heparin (Figure 4D) and heparan 
sulfate (data not shown) were not able to bind IL-34, even with high doses of up to 500 
µg/mL. 
 In light of these data, the chondroitin sulfate chains may be behind the IL-34 binding 
to the HEK Mock and HOS Mock cells, as well as the differential signalling pathways 
induced by M-CSF or IL-34 in the HEK M-CSFR. To explore this hypothesis, HEK M-CSFR 
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cells were then treated with chondroitinases A, B, C solution (chABC) to abrogate the 
chondroitin sulfates (CS) present at the cell surface prior to study of the M-CSF- or IL-34-
induced signalling pathways. Consistent with the results presented in Figure 1B, the M-CSFR 
was less activated after addition of 50 ng/mL of IL-34 compared to stimulation with the same 
dose of M-CSF, as illustrated by the phosphorylation levels of tyrosines 546, 708 and 723 
(Figure 5A). Interestingly, the chABC treatment markedly increased the levels of M-CSFR 
phosphorylations induced by IL-34 as demonstrated by the phosphorylation levels of M-
CSFR, whereas the response induced by M-CSF remained unchanged (Figure 5A). Similar 
results were obtained for ERK1/2. Both cytokines were also pre-incubated with 1, 3 or 10 
µg/mL CS salts for 1h at 37°C prior to their addition to the HEK M-CSFR cells. The addition 
of CS did not modulate the M-CSF-induced signalling pathway (Figure 5B). On the contrary, 
pre-incubation of CS with IL-34 led to increased phosphorylation of the receptor tyrosines 
708 and 723 (Figure 5B). Overall, these data clearly demonstrated that CS strongly regulates 
the biological activities of IL-34. 
 
3.4. IL-34 binding to chondroitin sulfate is independent of the receptor protein tyrosine 
SKRVSKDWDVHȕȗ5373ȕȗ 
฀R฀P฀T฀Pȕ฀/ȗ฀,฀ ฀a proteoglycan mainly expressed in the central nervous system, was recently 
identified on the glioblastoma cell line U251 as another receptor for IL-34 through its CS 
chains, explaining the role of the cytokine in brain development >27@. We then analysed 
฀R฀P฀T฀Pȕ฀/ȗ฀ expression in THP-1, TF-฀1฀,฀ ฀H฀O฀S฀ ฀M฀o฀c฀k฀ ฀a฀n฀d฀ ฀H฀E฀ ฀ ฀M฀o฀c฀k฀ ฀c฀e฀ ฀ ฀s฀.฀ ฀T฀h฀e฀ ฀R฀P฀T฀Pȕ฀/ȗ฀ ฀w฀a฀s฀ ฀n฀o฀t฀ 
expressed at either the transcriptional or the protein levels in any of these cells in contrast to 
the U251 cells used as a positive control (Figure 6). IL-34 binding to the HEK Mock and 
HOS Mock cells was consequently ฀i฀n฀d฀e฀p฀e฀n฀d฀e฀n฀t฀ ฀o฀f฀ ฀R฀P฀T฀Pȕ฀/ȗ฀. 
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3.5. The IL-34-induced migration of myeloid cells is syndecan-1 dependent 
Within the proteoglycan families, the syndecans control a lot of biological functions, such as 
angiogenesis, cytokine bioavailability, cell adhesion/interactions, etc. To investigate the 
functional involvement of syndecans in IL-34 biology, syndecans 1, 2 and 4 were individually 
overexpressed in the HEK M-CSFR cells and the phosphorylation levels of the M-CSFR were 
then analysed in the presence of IL-34. The, overexpression of syndecan-1 in the HEK M-
CSFR cells exacerbated the cell response to IL-34 (Figure 7A,B). Indeed, this overexpression 
induced stronger activation of the M-CSFR when IL-34 was added compared to the effects in 
non-transfected cells (NT) or cells transfected with an empty plasmid (Mock), as shown by 
the increased phosphorylations of 708, 723 tyrosines (Figure 7B). In contrast, the 
overexpression of syndecan-2 or -4 did not have any impact on M-CSFR activation by IL-34 
(Supplementary data 4). The addition of a blocking syndecan-1 antibody reduced the IL-34-
induced M-CSFR activation as measured by the levels of 708, 723 tyrosine phosphorylations 
in cells overexpressing syndecan-1 (Figure 7C). Anti-syndecan-1 antibody did not modulate 
by itself the M-CSFR phosphorylation while it upmodulated IL-34 effects on M-CSFR 
activation in non transfected cells (Figure 7D). To confirm the involvement of syndecan-1 in 
the IL-34 induced signalization, the syndecan-1 gene expression was knocked down using 
specific human syndecan-1 siRNA. As expected, syndecan-1 siRNA significantly down 
regulated the expression of the membrane protein as observed by flow cytometry (Figure 8A). 
Similarly to the addition of a blocking syndecan-1 antibody, the knocking down of syndecan-
1 upregulated the M-CSFR phosphorylations (Figure 8B). Similar results were obtained for 
ERK1/2. We then compared the IL-34 dose response on the M-CSFR phosphorylations in 
HEK M-CSFR subpopulations expressing differentially syndecan-1 (Supplementary data 5).  
The data showed that IL-34-induced M-CSFR phosphorylations reached a plateau in the 
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presence of 25 ng/mL for pTyr-708 whereas no plateau was observed in cells expressing 
higher syndecan-1 expression even in the presence of 100 ng/mL of IL-34 (Supplementary 
data 5). These data demonstrated that syndecan-1 was able to modulate the biological 
activities of IL-34 through the M-CSFR. 
To elucidate the functional implication of the syndecan-1/IL-34 interactions, we first 
analysed the expression of syndecan-1 in various cell types (Figure 9A). Syndecan-1 appears 
highly expressed by several cell types with hematopoietic (THP-1), mesenchymal (HOS 
Mock) and epithelial (HEK Mock) origin in contrast to U937 and TF-1 cells. IL-34 
significantly increased the migration of THP-1 cells compared to the control (Figure 9B, p < 
0.001). This IL-34-induced THP-1 cell migration was abolished by the addition of a blocking 
anti-syndecan-1 antibody. We then investigated the expression of syndecan-1 by human 
monocytes/macrophages (Figure 9C). CD14+ cells expressed a very low level of syndecan-1 
and interestingly, when CD14+ cells were differentiated toward M2a macrophages (CD14low, 
CD200R+, CD86+), differentiated cells highly expressed the syndecan-1 (Figure 9C). We then 
investigated the effects IL-34 on syndecan-1 expressing M2a macrophages. IL-34 
significantly stimulated the migration of M2a macrophages (Figure 9C, p < 0.001).  Similarly 
to the THP-1 cells, the addition of a blocking anti-syndecan-1 antibody totally inhibited the 
IL-34-induced M2a macrophage migration. Anti-syndecan-1 antibody had no effect on cell 
proliferation or on IL-34-associated monocyte survival (data not shown). Overall, these 
investigations demonstrated that IL-34 induced the migration of myeloid cells in a syndecan-1 
dependent manner. 
 
 
 
 18 
4. DISCUSSION 
IL-34 and M-฀C฀S฀F฀ ฀a฀r฀e฀ ฀c฀o฀n฀s฀i฀d฀e฀r฀e฀d฀ ฀a฀s฀ ฀“฀t฀w฀i฀n฀”฀ ฀c฀y฀t฀o฀k฀i฀n฀e฀s฀ ฀s฀h฀a฀r฀i฀n฀g฀ ฀c฀o฀ ฀ ฀o฀n฀ M-CSFR chains. 
However, while both cytokines have some functional overlaps, they also have specific 
activities, especially in the differentiation and activation of the monocyte/macrophage lineage, 
effects in favour of the existence of an additional, unknown receptor for IL-34 >13, 18-20@. 
Recently, Nandi et al. >27@ highlighted an alternative receptor for IL-34, the receptor protein 
฀t฀y฀r฀o฀s฀i฀n฀e฀ ฀p฀h฀o฀s฀p฀h฀a฀t฀a฀s฀e฀ ȕ฀/ȗ฀ ฀ ฀R฀P฀T฀Pȕ฀/ȗ฀ ฀, known to increase tyrosine phosphorylations of 
downstream prote฀i฀n฀s฀ ฀s฀u฀c฀h฀ ฀a฀s฀ ȕ-catenin, Src family kinases, focal adhesion kinase or Erk1/2. 
The present manuscript characterized a new binding mode for IL-34 to cells that express 
neither the M-CSFR, nor ฀t฀h฀e฀ ฀c฀h฀o฀n฀d฀r฀o฀i฀t฀i฀n฀ ฀s฀u฀ ฀f฀a฀t฀e฀ ฀p฀r฀o฀t฀e฀o฀g฀ ฀y฀c฀a฀n฀ ฀R฀P฀T฀Pȕ฀/ȗ฀.฀ ฀T฀his new IL-34 
binding is dependent on chondroitin sulfate chains, and syndecan-1 was identified as 
regulating the IL-34 activation levels of the M-CSFR. 
฀R฀P฀T฀Pȕ฀/ȗ฀ ฀i฀n฀t฀e฀r฀a฀c฀t฀s฀ ฀w฀i฀t฀h฀ ฀I฀L-34 through its chondroitin sulfate chains >27@. These 
authors demonstrated with enzymatic treatment and CS addition that chondroitin sulfate 
competed with IL-34 for binding to the extracellular domain of RPTPȕ฀/ȗ฀,฀ ฀r฀e฀v฀e฀a฀ ฀i฀n฀g binding 
฀d฀e฀p฀e฀n฀d฀e฀n฀c฀e฀ ฀o฀n฀ ฀R฀P฀T฀Pȕ฀/ȗ฀ ฀c฀h฀o฀n฀d฀r฀o฀i฀t฀i฀n฀ ฀s฀u฀ ฀f฀a฀t฀e฀ ฀c฀h฀a฀i฀n฀s฀.฀ Like R P฀T฀Pȕ /ȗ ,  c h฀o฀n฀d฀r฀o฀i฀t฀i n฀ ฀s฀u฀ f a t e  
moieties seem to be a prerequisite for IL-34 binding to syndecan-฀1฀.฀ ฀R฀P฀T฀Pȕ฀/ȗ฀ ฀a฀n฀d฀ ฀s฀y฀n฀d฀e฀c฀a฀n-1 
are transmembrane proteoglycans with common features. Both proteins have 
glycosaminoglycans on their ectodomain, and their intracellular C-terminal moiety interacts 
with proteins containing the PDZ domain >28,29@. The polymorphism of glycosaminoglycans 
attached to the protein core of syndecan-1 is due to different post-translational modifications 
and is directly linked to tissue-specific functions >30@. Thus, the degree of glycosylation of the 
extracellular domain explains the versatility of the syndecan family. Syndecan-1 belongs to a 
proteoglycan family including four members: syndecan-1 mainly expressed in epithelial cells 
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>31@, syndecan-2 mainly present in mesenchymal cells >32@, syndecan-3 mostly found in 
neuronal and cartilage tissues >33@ and syndecan-4 which is ubiquitously expressed >34@. All 
members of this family have heparan sulphate chains but only syndecan-1 and syndecan-3 
display chondroitin sulfate chains on their protein core. Syndecan-4 has been also described, 
to a lesser extent, in a chondroitin sulphate-associated form >35@. Based on these data, IL-34 
binding to the various syndecans must be considered according to tissue context and, for 
instance, IL-34 binding to syndecan-3 must not be excluded in the brain, especially regarding 
the importance of both IL-34 and syndecan-3 in the neuronal environment. 
 Proteoglycans are commonly devoted to numerous biological functions >36@ and it is 
accepted that they control the activities of a lot of cytokines/growth factors with or without 
glycosaminoglycan binding domains such as the heparin binding domain. Thus, the various 
proteoglycans serve as a reservoir for cytokines/growth factors and also modulate their 
induced signalling pathways by acting directly on the cytokine/growth factors-receptor 
interaction or by the regulation of cytokine activation and/or turnover >37@. In light of these 
pleiotropic activities, glycosaminoglycans may be involved in the sequestration of IL-34 at 
the cell membrane as revealed by the chondroitinase treatment that increased the 
phosphorylation levels of the M-CSFR induced by IL-34 (Figure 5A). Abrogation of 
membrane chondroitin sulphate chains may then reduce the trapping of IL-34 in these chains 
and may facilitate IL-34 binding to the M-CSFR (Figure 10A, B). Similarly, the pre-
incubation of chondroitin sulphate chains with IL-34 upmodulated the signal transduction 
through the M-CSFR (Figure 5B). In this context, soluble chondroitin sulphate chains may act 
as competitors to their homologous membrane forms and may limit IL-34 sequestration at the 
cell surface, facilitating its interaction with the M-CSFR (Figure 10C). Interestingly, soluble 
chondroitin sulfates compete with IL-฀γ฀δ฀ ฀f฀o฀r฀ ฀b฀i฀n฀d฀i฀n฀g฀ ฀t฀o฀ ฀t฀h฀e฀ ฀e฀x฀t฀r฀a฀c฀e฀ ฀ ฀u฀ ฀a฀r฀ ฀d฀o฀ ฀a฀i฀n฀ ฀o฀f฀ ฀R฀P฀T฀Pȕ฀/ȗ 
>27@, in contrast to the extracellular domain of M-CSFR (present data).  
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The co-receptor functions of proteoglycans are well illustrated by their interaction with the 
fibroblast growth factor and its receptor (FGF/FGFR). The FGF was the first growth factor 
identified as being dependent on heparin/heparan sulphate chains for its binding to the FGFR. 
The ternary complex FGF/FGFR/proteoglycans formed directly modulates the signalling 
pathways induced by the growth factor >38@. The co-receptor role of glycosaminoglycans has 
then also been demonstrated for epidermal growth factor (EGF) >39@, hepatocyte growth 
factor (HGF) >40@, vascular endothelial growth factor (VEGF) >41@, Wnt factors >42@ or 
members of the transforming growth factors (TGFs) >43@. In these cases, syndecan-1, via its 
heparan sulphate chains, acts as a co-receptor for these growth factors. Our present results 
suggest that syndecan-1 may also act as a modulator for the tyrosine kinase M-CSFR, but 
through its chondroitin sulfate chains. Syndecan-1 exhibits a stimulatory or inhibitory role, 
probably depending on its expression level. Thus, a low/moderate level of syndecan-1 may 
sequestrate IL-34 at the cell surface through its chondroitin sulfate chains, limiting the 
interaction between IL-34 and the M-CSFR (Figure 8D). The overexpression of syndecan-1 
induced significant phosphorylation of the M-CSFR, reinforced by the presence of IL-34.  
Interestingly, the overexpression of syndecan-1 modulate the pTyr723 of the M-CSFR that 
was already associated with the activation of specific signaling pathways (PI3K, Rho 
GTPases, paxilline, SFKs/Pyk2, etc) involved in cell migration >2, 44@. In contrast, a blocking 
anti-syndecan-1 antibody significantly reduced the effects of IL-34. The enhanced activation 
by syndecan-1 may be explained by the membrane proximity between the M-CSFR and 
syndecan-1, the biodistribution of syndecan-1 at the cell membrane being directly related to 
its expression level. IL-34 stimulation did not induce detectable signalling pathways 
(Supplementary data 2) in MOCK cells expressing syndecan-1 but not the M-CSFR and the 
฀R฀P฀T฀Pȕ฀/ȗ. These findings strengthen the hypothesis of a regulator for syndecan-1 on IL-34 
signalling through the M-CSFR. Previous works have already identified specialised docking 
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sites for other receptors in the syndecan extracellular domains, such as integrins and tyrosine 
฀k฀i฀n฀a฀s฀e฀ ฀r฀e฀c฀e฀p฀t฀o฀r฀s฀.฀ ฀T฀h฀u฀s฀,฀ Į฀vȕ฀γ฀ ฀i฀n฀t฀e฀g฀r฀i฀n฀ ฀a฀n฀d฀ ฀i฀n฀s฀u฀ ฀i฀n-like growth factor 1 receptor (IGF1R) ar  
captured by syndecan-1 to form a ternary receptor mainly expressed on tumour cells and 
endothelial cells and involved in the angiogenesis process >45@. Further investigations will be 
necessary to investigate the potential role of syndecan-1 in the IL-34 trapping. 
 Syndecan-1 is implicated in the control of cellular chemoattraction. Indeed, membrane 
proteoglycans, including the syndecan family, are responsible of a chemotactif gradient on 
endothelial cells linked to the adherence and migration of numerous circulating cells such as 
neutrophils >46@. Syndecan-1 mediated the osteoprotegerin-induced chemotaxis in human 
peripheral blood monocytes and may control by this mechanism, the inflammatory process 
and the bone remodelling >47, 48@. Proteoglycans like syndecan-1 contributes to the control of 
the pathogenesis of osteolysis >49, 50@. Thus, tumor-derived syndecan-1 is associated a 
crosstalk with bone and an increase of osteoclastogenesis >49, 50@. By interacting with 
syndecan-1, IL-34 may have a double involvement in osteoclastogenesis, by inducing the 
migration of myeloid osteoclast precursors expressing syndecan-1 and by substituting for M-
CSF in RANKL-induced osteoclastogenesis >5@. In addition, IL-34 was already shown to 
drives in vitro the polarization of macrophages towards an M2 immunosuppressive phenotype 
and function [4]. Several reports have described the accumulation of TAMs in tissue during 
the tumour development and TAMs are considered to facilitate the metastatic process [51]. 
We showed that syndecan-1 controls the IL-34-induced M2 macrophage migration (Figure 9), 
which can be related to the role of IL-34 in the biology of M2 macrophages [4]. The increased 
expression of syndecan-1 by macrophages was already observed during the myeloid 
differentiation and during the inflammatory process [52, 53]. These authors found a link 
between macrophage motility and the expression level of syndecan-1.  
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Syndecan-1 can now be added to the list of key regulators of IL-34 activities in addition to M-
CSFR ฀a฀n฀d฀ ฀R฀P฀T฀Pȕ฀/ȗ, but not of M-CSF. By controlling IL-34 bioavailability, by modulating 
the recruitment of M-CSFR chains or the affinity of IL-34 to the receptor chains, and/or by 
acting as a regulator signalling of the M-CSFR, syndecan-1 may play a part in the role of IL-
34 in development >22@, bone >5@ and inflammatory diseases >6@. Consequently, new therapies 
targeting the IL-34/M-CSFR axis must now take into account the existence of other receptors 
for the cytokine. 
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FIGURE LEGENDS 
Figure 1: IL-34 and M-CSF differentially activate the M-CSFR. (A) M-CSFR expression 
on the cell membrane of human cells analysed by flow cytometry. TF-1: erythroblastic 
leukaemia cell line, HEK293: embryonary cell line; HOS: osteosarcoma cell line; HL-60, U-
937 and THP-1: myeloid leukaemic cell lines; HOS M-CSFR and HEK M-CSFR: HOS and 
HEK stably overexpressing M-CSFR; HOS Mock and HEK Mock: HOS and HEK cell lines 
transfected with the empty control vector. The isotype IgG1 was used as the control (in grey 
on the graphs). (B-E) Western blot investigations of tyrosine phosphorylation patterns of M-
CSFR and Erk1/2 phosphorylation after addition of 50, 100 or 200 ng/mL of IL-34 or M-CSF 
for 1 to 30 minutes, in HEK M-CSFR (B), HOS M-CSFR (C), TF-1 M-CSFR (D) and THP-1 
cells (E). All experiments were performed three times in independent conditions and a 
representative set of experiments is shown.   
 
Figure 2: IL-34 binds to M-CSFR with a high affinity. Increasing concentrations of 125I-
labelled IL-34 (IL-34*) or 125I-labelled M-CSF (M-CSF*) were incubated for 60 min at 4°C 
with 106 cells and bound and unbound fractions were determined as described in 
฀“฀E฀x฀p฀e฀r฀i฀ ฀e฀n฀t฀a฀ ฀ ฀P฀r฀o฀c฀e฀d฀u฀r฀e฀s฀”฀.฀ ฀C฀u฀r฀v฀e฀ ฀f฀i฀t฀t฀i฀n฀g฀ ฀w฀a฀s฀ ฀p฀e฀r฀f฀o฀r฀ ฀e฀d฀ ฀a฀s฀ ฀d฀e฀s฀c฀r฀i฀b฀ed  i n฀ t฀h e  “ M฀a฀t฀e฀r฀i฀a฀ ฀s  a n d  
฀M฀e฀t฀h฀o฀d฀s฀”฀ ฀s฀e฀c฀t฀i฀o฀n฀.฀ ฀T฀y฀p฀i฀c฀a฀ ฀ ฀c฀u฀r฀v฀e฀s฀ revealing a specific binding fraction of iodinated M-CSF on 
HEK M-CSFR cells (A) and of iodinated IL-34 on HEK M-CSFR (B) and THP-1 cells (C). 
Table summarizing the binding mode of M-CSF and IL-34 on the cells of interest (D). These 
experiments are representative of three times in independent conditions and a representative 
experiment is shown.   
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Figure 3: A new IL-34 binding independent of the M-CSFR. (A-B) Inhibition binding 
assays were carried out on HEK M-CSFR cells. After incubation of HEK M-CSFR cells with 
a saturating concentration of 125I-labelled IL-34 (IL-34*), increasing doses of unlabelled IL-
34 (A) or unlabelled M-CSF (B) were added to the cells. (C) Binding of 125I-labelled IL-34 
was assessed by Scatchard assay on HEK Mock cells which did not express the M-CSFR. (D) 
Competition assay of 125I-labelled IL-34 with unlabelled IL-34 was performed on HEK Mock 
cells. (E) Binding of HEK Mock cells on IL-34 or M-CSF spotted on a chip analysed by 
Surface Plasmon Resonance. All experiments were repeated three times in independent times. 
 
Figure 4: IL-34 binds to chondroitin sulfate but not to heparin/heparan sulfate chains. 
Interactions between IL-34 and glycosaminogycans were studied by surface plasmon 
resonance technology. Chondroitin sulfate A (A), chondroitin sulfate B (B), chondroitin 
sulfate C (C), or heparin (D) were injected on immobilised IL-34 using the parameters 
described in the ฀“฀M฀a฀t฀e฀r฀i฀a฀ ฀s฀ ฀a฀n฀d฀ ฀M฀e฀t฀h฀o฀d฀s฀”฀ ฀s฀e฀c฀t฀i฀o฀n฀. 
 
Figure 5: Chondroitin sulfate chains regulate the M-CSFR phosphorylations induced by 
IL-34. (A) HEK M-CSFR cells were treated with a mixture of chondroitinases A, B and C for 
90 min at 37°C, before addition of 50 ng/mL of M-CSF or IL-34 for 5 min. (B) HEK M-
CSFR cells were pre-incubated with 1, 3 or 10 µg/mL of chondroitin sulfate salts for 90 min 
at 37°C before addition of 50 ng/mL of M-CSF or IL-34 for 5 min. The phosphorylation 
patterns of the M-CSFR and ERK1/2 were assessed by Western blot. Total forms of M-CSFR, 
ERK1/2 ฀a฀n฀d฀ ȕ-actin were used as a loading control. Bar graphs show relative densitometric 
values of pTyr-723 normalized to the M-CSFR. Similar densitometric measurments were 
obtained for pTyr-746 or pTyr-708, normalized to the M-CSFR or to ȕ-actin. These 
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experiments were performed three times in independent conditions and a representative 
experiment is shown.   
 
Figure 6: HEK, HOS, THP-1 and TF-1 do not express the receptor protein tyrosine 
SKRVSKDWDVH5373ȕȟ The expression of the receptor protein tyrosi฀n฀e฀ ฀p฀h฀o฀s฀p฀h฀a฀t฀a฀s฀e฀ ฀R฀P฀T฀Pȕ฀/ȟ฀ 
was assessed in the different cells used in the study both at the transcriptional level by 
quantitative RT-PCR (A), where expression was normalised against GAPDH mRNA levels, 
฀a฀n฀d฀ ฀a฀t฀ ฀t฀h฀e฀ ฀p฀r฀o฀t฀e฀i฀n฀ ฀ ฀e฀v฀e฀ ฀ ฀b฀y฀ ฀W฀e฀s฀t฀e฀r฀n฀ ฀ ฀ ฀o฀t฀,฀ ฀w฀h฀e฀r฀e฀ ȕ-actin was used as a loading control (B). 
These experiments were performed three times in independent conditions and a representative 
experiment is shown.   
 
Figure 7: Syndecan-1 modulates the M-CSFR phosphorylations induced by IL-34. HEK 
M-CSFR were transiently transfected with a plasmid-encoding human syndecan-1. (A) 
Syndecan-1 expression analysed by flow cytometry, 48 h after transient transfection. 
Syndecan-1 expression in Mock M-CSFR transfected with an empty vector of syndecan-1 
(empty histogram). Syndecan-1 overexpressing cells were stimulated with or without 50 
ng/mL of IL-34 for 5 min (B) in the presence or absence of 20 Pg/mL of syndecan-1 blocking 
antibody pre-incubated for 90 min (C). Similar experiments were performed on HEK M-
CSFR (non transfected for syndecan-1) with or without 100 ng/mL of IL-34 and/or 10 Pg/ml 
of anti-syndecan-1 antibody for 1 and 5 minutes (D). M-CSFR- and ERK1/2- 
phosphorylations were assessed by Western Blot, with the M-CSFR, ERK1/2 total forms of 
and GAPDH as a loading control. Bar graphs show relative densitometric values of pTyr-723 
and pTyr-708 normalized to the M-CSFR. These experiments were performed four times in 
independent conditions and a representative experiment is shown.   
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Figure 8: Syndecan-1 siRNA increases the phoshorylation M-CSFR induced  by IL-34.  
The syndecan-1 gene expression was knocked down using specific human syndecan-1 siRNA. 
(A) Syndecan-1 expression analysed by flow cytometry, 48 h after siRNA transfection. (B) 
Syndecan-1 knocked down cells were stimulated with or without 50 ng/mL of IL-34 for 5 min 
and M-CSFR-, ERK1/2-phosphorylations were assessed by Western Blot, with the total forms 
of M-CSFR and ERK1/2 as a loading control. Bar graphs show relative densitometric values 
of pTyr-723 normalized to the M-CSFR. Similar densitometric measurments were obtained 
for pTyr-708, normalized to the M-CSFR or to GAPDH. A representative experiment out of 
three independent experiments is shown.   
 
 
Figure 9: IL-34 increases the migration of myeloid cells through the syndecan-1. (A) 
Syndecan-1 expression by various myeloid, mesenchymal and epithelial cells analysed by 
flow cytometry. (B) THP-1 cells were preincubated with antibody to syndecan-1 (B-B4) or -4 
the correspond isotype matched IgG (IgG1) for 15 min. After washing twice, migration 
toward IL-34 (100 ng/mL) was tested for 6 hours. (C) M2a macrophage were obtained from 
CD14+ cells isolated from peripheral blood of healthy donors, cultured and differentiated in in 
RPMI  supplemented with 1% human serum, 1% penicillin/streptomycin, 50 ng/mL of IL-4 
for 5 days. The expression of syndecan-1 and their phenotype (CD14low, CD220R+, CD86+) 
were analysed by flow cytometry. M2a cells were collected by gentle scraping and their 
migration ability in the presence of IL-34 with or withoutan a blocking anti-syndecan-1 
antibody was assessed as described for the THP-1 cells.  The histograms show the percentage 
of the migrated cells compared to the IgG1 control. Graphs represent the mean ±SD of three 
independent experiments done in triplicate in each case. A Kruskal-Wallis test was performed 
฀f฀o฀ ฀ ฀o฀w฀e฀d฀ ฀b฀y฀ ฀a฀ ฀ ฀u฀n฀n฀’฀s฀ ฀p฀o฀s฀t-hoc between all the conditions. *** p < 0.001. 
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Figure 10: Schematic diagram hypothesizing the functional involvement of syndecan-1 
in the bioavailability and activities of IL-34. Potential interactions of IL-34 with M-CSFR, 
Syndecan-1 and chondroitin sulfates in control conditions (A), after chondroitinase ABC 
treatment (B), in the presence of exogenous chondroitin sulfate chains (C), and according to 
the levels of syndecan-1 expression (D). 
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ABSTRACT 
IL-34 is a challenging cytokine sharing functional similarities with M-CSF through M-
CSFR activation. It also plays a singular role that has recently been explained in the brain, 
through a ฀b฀i฀n฀d฀i฀n฀g฀ ฀t฀o฀ ฀t฀h฀e฀ ฀r฀e฀c฀e฀p฀t฀o฀r฀ ฀p฀r฀o฀t฀e฀i฀n฀ ฀t฀y฀r฀o฀s฀i฀n฀e฀ ฀p฀h฀o฀s฀p฀h฀a฀t฀a฀s฀e฀ ฀R฀P฀T฀Pȕ฀/ȗ฀.฀ The aim of this paper 
was to look for alternative binding of IL-34 on other cell types. Myeloid cells (HL-60, U-937, 
THP-1) were used as cells intrinsically expressing M-CSFR, and M-CSFR was expressed in 
TF-1 and HEK293 cells. IL-34 binding was studied by Scatchard and binding inhibition 
assays, using 125I-radiolabelled cytokines, and surface plasmon resonance. M-CSFR activation 
was analysed by Western blot after glycosaminoglycans abrasion, syndecan-1 overexpression 
or repression and addition of a blocking anti-syndecan antibody. M-CSF and IL-34 induced 
different patterns of M-CSFR phosphorylations, suggesting the existence of alternative 
binding for IL-34. Binding experiments and chondroitinase treatment confirmed low affinity 
binding to chondroitin sulfate chains on cells lacking both M-฀C฀S฀F฀R฀ ฀a฀n฀d฀ ฀R฀P฀T฀Pȕ฀/ȗ. Amongst 
the proteoglycans with chondroitin sulphate chains, syndecan-1 was able to modulate the IL-
34-induced M-CSFR signalling pathways. Interestingly, IL-34 induced the migration of 
syndcean-1 expressing cells. Indeed, IL-34 significantly increased the migration of THP-1 and 
M2a macrophages that was inhibited by addition of a blocking anti-syndecan-1 antibody.  
This paper provides evidence of alternative binding of IL-34 to chondroitin sulfates and 
syndecan-1 at the cell surface that modulates M-CSFR activation. In addition, IL-34-induced 
myeloid cell migration is a synedcan-1 dependent mechanism. 
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1. INTRODUCTION 
The discovery of interleukin-34 (IL-34) in 2008 upset the functional biological concepts 
that had been admitted for many years between Macrophage Colony Stimulating Factor (M-
CSF) and its receptor, the M-CSF receptor (M-CSFR) >1,2@. Like M-CSF, IL-34 promotes the 
survival and proliferation of monocytes, as well as their differentiation into macrophages >3@. 
Macrophages induced by IL-34 have phenotypes and functions that are similar to those 
differentiated by M-CSF, as both cytokines polarize these macrophages into 
immunosuppressive macrophages M2 >4@. In addition, and in association with the Receptor 
Activator of Nuclear Factor Kappa-B Ligand (RANKL), IL-34 can replace M-CSF to induce 
osteoclast formation by stimulating the proliferation and adhesion of osteoclast precursors >5@. 
The cytokine also overlaps with the roles played by M-CSF in inflammation in degenerative 
bone diseases such as rheumatoid arthritis >6@ and periodontal inflammation >7@. All these 
effects are mediated by a cell-surface tyrosine kinase activity receptor, M-CSFR, encoded by 
the proto-oncogene c-fms, and also called c-fms, CD115 or CSF-1R >8@. The homodimeric 
cytokines M-CSF or IL-34 bind in a close way to the extracellular domain of M-CSFR, but 
with a different binding mode >9,10@, leading to receptor dimerization and differential auto-
phosphorylation on its eight tyrosine residues >11@. M-CSF/M-CSFR and IL-34/M-CSFR 
crystals have quite a similar shape, except a higher stability for the IL-34/M-CSFR complex 
>12@. Chihara et al. showed some differences in the kinetics of M-CSFR phosphorylations and 
in the nature and intensity of phosphorylated tyrosine residues after M-CSF or IL-34 binding, 
which partly explains their ability to differentially activate the monocyte/macrophage lineage 
>13@. 
MCSF-R knockout mice >14@ exhibit a similar but more pronounced phenotype than 
op/op mice >15,16@ characterized by a more severe osteopetrosis and reduction of tissue 
macrophages. This osbservation suggested the existence of another ligand for the M-CSFR, 
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and IL-34 was a perfect candidat. Although IL-34 expression under the promoter of the M-
CSF gene rescues the phenotype of op/op mice, the cytokine also plays singular roles during 
brain development >17@. Microglia and Langerhans cells effectively decrease dramatically in 
IL-34 knockout mice, as in M-CSFR deficient mice, while monocytes, lymphoid tissue 
macrophages and dendritic cells are not affected. Besides, op/op mice show quite a 
conventional development of these cells >18-20@. These results identify specific IL-34 activity 
during embryogenesis and tissue homeostasis, and make it possible to better understand the 
tissue distribution and independent activity of IL-34 >21@. 
IL-34 is highly expressed in both post-natal and adult brains, whereas M-CSFR 
expression, which is maximal in early development, dramatically decreases in adult brains 
>22@. High expression of IL-34 despite an almost undetectable expression of its receptor 
suggests the existence of other receptors for the cytokine. In spite of overlapping and 
complementary activities between M-CSF and IL-34 through M-฀C฀S฀F฀R฀ ฀a฀c฀t฀i฀v฀a฀t฀i฀o฀n฀,฀ ฀t฀h฀e฀ ฀“฀M-
฀C฀S฀F฀ ฀t฀w฀i฀n฀”฀ may also exert specific functions independently of this receptor. The present study 
thus investigates a new binding mode for IL-34 that may modulate the bioavailability and/or 
activities of this cytokine. This paper provides evidence of syndecan-1 as a new molecular 
actor in the M-CSF/IL-34/M-CSFR triad and proposes one explanation for the differential 
activation of the M-CSFR observed after M-CSF and IL-34 stimulation. 
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2. MATERIAL AND METHODS 
All experiments described in the manuscript were repeated at least three times in independent 
experiments and representative experiments are shown. 
 
2.1. Reagents 
Recombinant human Macrophage-Colony Stimulating Factor (M-CSF), human interleukin-34 
(IL-34), human M-CSF Receptor (M-CSFR), mouse IgG1 (control isotype) and antibody anti-
human M-CSFR ฀w฀e฀r฀e฀ ฀o฀b฀t฀a฀i฀n฀e฀d฀ ฀f฀r฀o฀ ฀ ฀R฀ ฀ ฀ ฀S฀y฀s฀t฀e฀ ฀s฀ ฀ ฀ ฀b฀i฀n฀g฀d฀o฀n฀,฀ U฀ .  ฀ ฀i฀a c฀ o n e฀   e s a n c ฀on, 
France) kindly provided the murine B-B4 anti-syndecan 1 (CD138) IgG1 monoclonal 
antibody.  Antibodies directed against human CD14, human CD200R and human CD86 were 
purchased from Biolegend (Saint Quentin en Yvelines, France). Antibodies directed against 
human P-MCSFR, P-Erk1/2, P-mTor,  P-Akt and the total form of proteins were purchased 
from Cell Signalling (Ozyme, Saint Quentin Yvelines, France). Anti-ȕ actin and total 
phosphorylated tyrosine antibodies were respectively provided by Sigma-Aldrich (Saint 
Quentin Fallavier, France) and Millipore (Molsheim, France). Anti-Receptor Protein Tyrosine 
Phosphatase ฀ ฀R฀P฀T฀Pȕ฀/ȗ฀, C-19 clone) and HRP-conjugated secondary antibodies were obtained 
from Santa-Cruz (CliniSciences, Nanterre, France). Chondroitin sulfate salts from shark 
cartilage, heparin, heparan sulfate salts and chondroitinases A, B, C were purchased from 
Sigma-Aldrich (Saint Quentin Fallavier, France).  
 
2.2. Cell cultures 
The cell lines used in the present study were purchased from the American Tissue Cell 
Collection (ATCC, Molsheim, France). HEK293 (HEK), osteosarcoma MNNG/HOS 
(ATCC® Number: CRL-1547฀™) (HOS) were cultured in DMEM (Dulbecco's Modified 
Eagle's Medium, Lonza, Levallois-Perret, France) supplemented with 10% foetal bovine 
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serum (FBS; HyclonePerbio, Bezons, France) and 2 mmol/L of L-glutamine. HL-60, U937, 
THP-1 and TF-1cell lines were maintained in RPMI (Roswell Park Memorial Institute, 
Lonza) supplemented with 10% FBS. In addition, TF-1 cells were cultured in the presence of 
3 ng/mL of G-MCSF according to ATCC recommendations. The human U251 glioblastoma 
cell line was kindly provided by Dr Mylène Dorvillius (ATLAB Pharma, Nantes, France) and 
cultured in DMEM supplemented with 10 % FBS. 
 
2.3. Cloning of the human M-CSFR gene and cell transfection 
The human M-CSFR gene (NM_005211.3) was cloned in a pCDNA3.3 TOPO TA vector 
(Life Technologies, Villebon sur Yvette, France) from the cDNA from a healthy donor 
CD14+. CD14+ cells were initially isolated from human peripheral blood donors provided by 
the French blood bank institute (Etablissement Français du Sang, Nantes, France, 
authorization number: NTS 2000-24), by using MACS microbeads (MiltenyiBiotec, 
Germany) as previously described >5@. The RT-PCR product was obtained using the following 
primer sequences: Forward ฀5฀’-CACCATGGGCCCAGGAGTTCTGCTGCT-฀γ฀’ and Reverse 
฀5฀’-AACTCCTCAGCAGAACTGATAGTTGTTGGGCTGCA-฀γ฀’, and fully sequenced to 
check for the absence of functional mutations based on the sequences already published in the 
data bases. 
 Embryonic HEK293 cells and osteosarcoma HOS cells were transfected as described 
below with the pCDNA3 empty plasmid or the pCDNA3 plasmid containing the M-CSFR 
gene. To obtain a polyclonal population expressing the membrane M-CSFR, 5x106 cells were 
then stained with phycoerythrin (PE) conjugated antibodies directed against the M-CSFR and 
sorted out on a FACSAria III (Beckman Coulter, Villepinte, France). The cells expressing the 
M-CSFR were named respectively HEK M-CSFR and HOS M-CSFR. The cells transfected 
with the empty pCDNA3 vector were called HEK Mock and HOS Mock. Erythroblastic TF-1 
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cells were transfected using an Amaxa® Cell Line Nucleofector® Kit by Lonza. Cell sorting 
was also carried out to isolate M-CSFR expressing cells (TF-1 M-CSFR).  
 
2.4. RNA isolation and real-time PCR 
Total RNA was extracted using NucleoSpin®RNAII (Macherey Nagel, Duren, Germany) 
with one stage of DNase I treatment (25 units, 15 min) to prevent genomic contamination. 1 
ȝ฀g฀ ฀o฀f฀ ฀t฀o฀t฀a฀ ฀ ฀R฀N฀ ฀ ฀w฀a฀s฀ ฀u฀s฀e฀d฀ ฀f฀o฀r฀ ฀f฀i฀r฀s฀t฀ ฀s฀t฀r฀a฀n฀d฀ ฀c฀ ฀N฀  synthesis using the ThermoScript RT-PCR 
System (Invitrogen). Real-time PCR was performed on 20 ng of reverse transcribed total 
RNA (cDNA), 300 nM of primers and 2x SYBR Green Supermix (Biorad, Marnes-la-
Coquette, France). The analysis was performed according to the method described by 
Vandesompele et al. [23] using human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
as the invariant control. Standard curves were obtained using decreasing quantities of cDNA 
from the U251 cell line to validate the ฀R฀P฀T฀Pȕ฀/ȗ฀ ฀p฀r฀i฀ ฀e฀r฀s฀ ฀a฀c฀c฀o฀r฀d฀i฀n฀g฀ to the MIQE guidelines 
>24@. The sense and antisense primers used were: ฀R฀P฀T฀Pȕ฀/ȗ Forward: ฀5฀’-
GCAGAGCTGTACTGTTGACTT-3฀’, R฀e฀v฀e฀r฀s฀e฀:฀ ฀5฀’-TGTGCTAGCTTAACCCTGCT-฀γ฀’฀; 
GAPDH Forward: ฀5฀’-TGGGTGTGAACCATGAGAAGTATG-฀γ฀’, Reverse: ฀5฀’-
GGTGCAGGAGGCATTGCT-฀γ฀’. 
 
2.5. M-CSF and IL-34 binding assays  
M-CSF and IL-34 were radio-labelled with iodine-125 (125I) (which has specific radioactivity 
of around 2,000 cpm/fmol) using the chloramine T method, as described by Tejedor and 
Ballesta >25@ and Godard et al >26@. To determine the ability to bind to the cells of both 
cytokines, 1x106 cells were incubated with increasing concentrations of iodinated M-CSF or 
IL-34 (up to 1nM) for 1 h at 4°C. Non-specific binding was determined in the presence of 
100-fold excess of the corresponding unlabelled cytokine. Specific binding was subsequently 
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obtained by subtraction of this non-specific binding from the total binding signal. Regression 
analysis of the binding data was carried out using a one-site equilibrium binding equation 
(Graphit; Erithacus Software, Staines, U.K.) and data were plotted in the Scatchard coordinate 
system. Cross competition binding curves were obtained by adding simultaneously to the cells 
increasing amounts of a competitor cytokine together with a fixed, non-saturable 
concentration of a labelled cytokine. The inhibition curves obtained were analysed with an 
equation for competitive inhibition between two ligands for a common binding site. Curve 
fittings were performed using the Graphit data analysis programme. 
 
2.6. Surface Plasmon Resonance (SPR) assays 
The SPR experiments were carried out on a BIAcore 2000 biosensor (BIAcore, Uppsala, 
Sweden). Recombinant human IL-34 (5µg/mL, in 5 mM maleate buffer pH=6.2) was 
covalently linked to the dextran matrix of a CM5 sensor chip (BIAcore, Uppsala, Sweden), 
previously activated with an ethyl (dimethylaminopropyl) carbodiimide/ N-
hydroxysuccinimide (EDC/NHS) mixture. Immobilisation levels in the 1300 RU range were 
then obtained. Residual active groups were inactivated by injection of ethanolamine 1M 
pH=8.5 for 10 min. The binding of decreasing concentrations of chondroitin sulfate salts, 
heparin or heparan sulfate salts was monitored, from 100 µg/mL and with a serial dilution of 
1:3. Concentrations up to 500 µg/mL were assessed for the heparin and heparan sulfate. The 
flow rate was around 30 µL/min, and the chip was regenerated with 20 mM NaOH between 
each cycle. The resulting sensorgrams were fitted using BiaEval 4.1 software.  
Cell binding experiments were carried out in the SPRiplex II. The SPRi biochip-CH 
(H0550) was activated with an EDC/NHS mixture, and 200 µg/mL IL-34 was spotted on it 
with a 500µM tip for 30 min. The protein binding capacity of the IL-34 was controlled by 
injections of 1 and 2 µg/mL of recombinant human M-CSFR on the chip after each 
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regeneration cycle performed with 10mM glycine pH=1.5. HEK Mock cells (2x105 cells/mL) 
were then injected on to the chip at 20 µL/min for 10 min. 
 
2.7. Flow-cytometry experiments 
Membrane expression of the M-CSFR, syndecan-1, CD14, CD220R, CD86 were assessed 
with flow cytometry (Cytomics FC500; Beckman Coulter). Cells were incubated with PE-
conjugated anti-human M-CSFR antibody or mouse IgG1 as the control for 30 min. For 
syndecan-1 expression, the cells were first incubated for 90 min at 4°C with the anti-
syndecan-1 B-B4, before incubation with the PE-conjugated secondary antibody for 60 min. 
Similar method was used to analyse CD14, CD220R and CD86 expression. M-CSFR and 
syndecan-1 expressions were analysed using the CXP Analysis software 2.2 (Beckman 
Coulter).  
 
2.8. Western Blot Analysis 
The cells were collected in a RIPA buffer (10 mM Tris pH8, 1 mM EDTA, 150 mM NaCl, 
1% NP40, 0.1% SDS containing a cocktail of protease and phosphatase inhibitors: 1 mM 
sodium orthovanadate (Na2VO4), 1 mM phenylmethylsulforyl fluoride (PMSF), 10 mM 
sodium fluoride (NaF), 10 mM N-฀e฀t฀h฀y฀ ฀ ฀a฀ ฀e฀i฀ ฀i฀d฀e฀ ฀ ฀N฀E฀M฀ ฀,฀ ฀β฀ ȝ฀g฀/฀ ฀ ฀ ฀ ฀e฀u฀p฀e฀p฀t฀i฀n฀ ฀a฀n฀d฀ ฀1฀ ȝ฀g฀/฀ ฀ ฀ 
pepstatine). The protein concentration was determined using a BCA (bicinchoninic acid) 
prote฀i฀n฀ ฀a฀s฀s฀a฀y฀ ฀ ฀S฀i฀g฀ ฀a฀ ฀ ฀ ฀d฀r฀i฀c฀h฀ ฀.฀ ฀δ฀0฀ ȝ฀g฀ ฀o฀f฀ ฀t฀o฀t฀a฀ ฀ ฀p฀r฀o฀t฀e฀i฀n฀ ฀e฀x฀t฀r฀a฀c฀t฀s฀ ฀w฀e฀r฀e฀ ฀p฀r฀e฀p a r e d  ฀i฀n฀ ฀a฀ ฀L฀a฀e฀ ฀ ฀i  
buffer (62.5 mM Tris฀–HCl, pH 6.8, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.001% 
bromophenol blue) and then separated by SDS-polyacrylamide gel electrophoresis. After 
electrophoretic transfer, the immobilon-P membranes (Millipore, Molsheim, France) were 
blotted with the antibodies referenced in the reagents section. The membranes were then 
probed with secondary antibodies coupled with horseradish peroxidase. Antibody binding was 
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visualised with a Pierce enhanced chemiluminescence (ECL) kit (ThermoSientific, Illkirch, 
France). The luminescence detected with a Charge Couple Device (CCD) camera was 
quantified using the GeneTools programme (Syngene, Cambridge, United Kingdom). 
 
2.9. siRNA gene silencer 
The syndecan-1 gene expression was knocked down using specific human syndecan-1 siRNA 
(Ambion, France) and the INTERFERinTM transfection reagent (Polyplus transfection, 
France). 700 x 103 HEK M-CSFR cells per well were seeded in a 6-well plate 1 day before 
transfection. In each well 50 nm siRNA (Syndecan-1 siRNA : ref#s12634 ; Ambion® 
Silencer® Negative Control #1 : ref#AM4611) duplexes diluted in serum-free medium were 
฀i฀n฀c฀u฀b฀a฀t฀e฀d฀ ฀w฀i฀t฀h฀ ฀β฀ ȝ฀ ฀ ฀o฀f฀ ฀I฀N฀T฀E฀R฀F฀E฀R฀i฀nTM for 30 min at room temperature. The expression of 
membrane syndecan-1 was measured by flow cytometry. 48 h after the transfection, 50 ng/mL 
of IL-34 (5 min, 37°C) were added to the cells and M-CSFR activation was determined by 
Western blot as previously described. 
 
2.10. M2a macrophage differentiation and cell migration assays 
CD14+ monocytes were isolated from peripheral blood of 3 healthy donors as previously 
described in paragraph 2.3. For M2a macrophage differentiation, CD14+ cells were cultured in 
RPMI (Roswell Park Memorial Institute medium, Lonza) supplemented with 1% Human 
Serum (Invitrogen), 1% penicillin/streptomycin, 50 ng/mL of IL-4 (R&D System) for 5 days. 
Half volume of the medium was renewed at day 2. After the differentiation culture period, 
M2a adherent cells were collected by gentle scraping. Their phenotype was analysed by flow 
cytometry (CD14low, CD220R+, CD86+) before use in migration assays. 2x105 M2a 
macrophages or 5x10
5 
THP-1 were pre-treated for 30 min at 37°C with a blocking anti 
syndecan-1 antibody (SDC-1 Ab, B-B4) or the corresponding isotype (IgG1 Ab). Cell 
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migration was then assessed using a 8µm Boyden chamber (top well) in RPMI 1% FCS, with 
or without 100 ng/mL of IL-34 at the bottom well. Cells migrating at the bottom well were 
counted after 6 hours of culture. Each experiment was done in triplicate and repeated three 
times. 
 
2.11. Statistical analysis 
Results were analyzed using a Kruskal-฀W฀a฀ ฀ ฀i฀s฀ ฀t฀e฀s฀t฀ ฀w฀a฀s฀ ฀p฀e฀r฀f฀o฀r฀ ฀e฀d฀ ฀f฀o฀ ฀ ฀o฀w฀e฀d฀ ฀b฀y฀ ฀a฀ ฀ ฀u฀n฀n฀’฀s฀ ฀p฀o฀s฀t-
hoc between all conditions using GraphPad InStat v3.02 software. The results of the migration 
assays are given as a mean ± SD of three independent experiments done in triplicate. Results 
฀w฀e฀r฀e฀ ฀c฀o฀n฀s฀i฀d฀e฀r฀e฀d฀ ฀s฀i฀g฀n฀i฀f฀i฀c฀a฀n฀t฀ ฀a฀t฀ ฀p฀ ฀v฀a฀ ฀u฀e฀s฀ ฀≤฀ ฀0฀.฀0฀5฀. All Western blots were performed three or four 
times in independent experiments and a representative blot was changed in each figure. 
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3. RESULTS 
3.1. IL-34 and M-CSF induce differential activation of the M-CSFR  
We first analysed the membrane expression of M-CSFR in various human cells with flow 
cytometry. As expected, the HL-60, U937 and THP-1 myeloid cell lines intrinsically 
expressed this cytokine receptor, in contrast to the erythroblastic TF-1, epithelial HEK293 and 
HOS osteosarcoma cells which did not express the M-CSFR (Figure 1A). The lack of M-
CSFR expression by the TF-1, HEK and HOS cells was confirmed by quantitative PCR (data 
not shown). Marked expression of the M-CSFR at the cell membrane was observed in M-
CSFR transfected TF-1, HEK and HOS cells (Figure 1A).  
Based on these observations, we investigated the functionality of the receptor by 
studying the cell signalling induced by M-CSF and IL-34, the two identified ligands of the M-
CSFR (Figures 1B-E). In HEK M-CSFR cells, both cytokines induced in a dose- (data not 
shown) and time-dependent manner the tyrosine 546, 699, 708, 723 and 923 phosphorylation 
of the receptor฀’฀s intracellular chains with a peak at 5 min (Figure 1B). Similarly, M-CSF and 
IL-34 induced the phosphorylation of Erk1/2. Compared to M-CSF, IL-34 induced a weaker 
activation of the signalling pathway mediated by M-CSFR activation, at the same dose and 
time (Figure 1B). In the HOS M-CSFR cells, high doses of IL-34 (200 ng/mL) appeared more 
efficient at inducing the phosphorylation of the M-CSFR compared to M-CSF, unlike low 
doses of the cytokine (50 ng/mL) (Figure 1C). This higher activation of the M-CSFR by IL-34 
was also observed with 100 ng/mL of cytokine in the TF-1 M-CSFR cells as demonstrated by 
fast and huge phosphorylation levels of the M-CSFR (Figure 1D), data in agreement with 
Chihara et al. >13@. We then investigated M-CSFR activation in the THP-1 cells which 
intrinsically expressed the receptor chains (Figure 1E). Consistent with the findings obtained 
with the TF-1 M-CSFR cells, the M-CSFR and MAPK downstream signalling pathways were 
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more activated by IL-34 than by M-CSF (Figure 1E, Supplementary data 1A). Similar results 
were obtained in the U937 cells (Supplementary data 1B). Overall, these data revealed that 
IL-34 and M-CSF differentially activated the M-CSFR signalling pathway according to the 
cell type studied. 
 
3.2. IL-34 binds to HEK and HOS cells lacking the M-CSFR  
In light of the differential signalling pathway induced by IL-34 and M-CSF, binding assays 
using 125I-ligands were carried out on the different cell lines of interest. A saturation binding 
curve was obtained, which after Scatchard transformation, made it possible to estimate the 
affinity of IL-34 for the membrane M-CSFR. 125I-IL34 bound all cell lines studied with an 
equilibrium dissociation constant around 2 nM, 0.55 nM, 1 nM and 0.75 nM for U937, THP-
1, HEK M-CSFR and HOS M-CSFR cells respectively (Figure 2A-D). As expected, 125I-
MCSF bound to the HEK M-CSFR and HOS M-CSFR with a similarly high affinity (Kd = 
0.35 nM). These data demonstrated the capacity of IL-34 to bind with a high affinity to cell 
lines expressing the M-CSFR (Figure 2D).  
We next assessed the potency of recombinant IL-34 and/or M-CSF to compete with 
125I-IL34 binding to cell surface receptors (Figures 3A, B). The results demonstrated that cold 
IL-34 and M-CSF differentially competed with the 125I-IL34 binding sites expressed in the 
HEK M-CSFR, as revealed by the slope factor of the inhibition curves (0.8 and 2 for M-CSF 
and IL-34 respectively) (Figure 3A,B). Similar results were obtained with the HOS M-CSFR 
cells (data not shown). 125I-IL34 binding assays were then performed in HEK Mock cells 
transfected with the empty control vector that did not express the M-CSFR (Figure 1A, Figure 
3C). Surprisingly, specific 125I-IL34 specific binding sites were detected at the surface of the 
HEK Mock cells (Figure 3C,D). This binding was characterised by a lower affinity (Kd = 14.6 
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nM) than those observed in the HEK M-CSFR (Figure 2B). In contrast to 125I-IL34, 125I-M-
CSF did not bind to cells lacking the M-CSFR (Supplementary data 2). Complementary SPR 
experiments reinforced these results and confirmed the ability of the HEK Mock cells to bind 
to recombinant IL-34 spotted on a sensorchip, in contrast to recombinant M-CSF, as measured 
by the increasing percentage of reflectivity (Figure 3E). The results clearly demonstrated an 
additional binding mode for IL-34 independent of the M-CSFR.  
 
3.3. IL-34 binding to chondroitin sulfate chains modulates M-CSFR activation 
As IL-34 bound with a relatively low affinity to cells that did not express the M-CSFR (HEK 
Mock and HOS Mock), cell signalling was further investigated in these cells after stimulation 
with a high dose of IL-34 (200ng/mL). As shown in Supplementary data 3, the profile of the 
phosphorylated tyrosines was not modified after IL-34 stimulation (Supplementary data 3A) 
and no modulation of the different signalling pathways such as mTor, Akt, (Supplementary 
data 3B), ȕ-catenin, p38 and Erk1/2 (data not shown) was observed in the presence of IL-34. 
Consistent with the ability of IL-34 to bind to glycosaminoglycans >27@, we assessed the IL-
34 binding to chondroitin sulfate and heparin/heparan sulfate chains by SPR. The SPR 
sensorgrams revealed a low affinity binding of the various types of chondroitin sulfate to IL-
34, with a Kd of 132 nM, 775 nM and 16.1 nM for chondroitin sulfates A (Figure 4A), B 
(Figure 4B) and C (Figure 4C) respectively. On the contrary, heparin (Figure 4D) and heparan 
sulfate (data not shown) were not able to bind IL-34, even with high doses of up to 500 
µg/mL. 
 In light of these data, the chondroitin sulfate chains may be behind the IL-34 binding 
to the HEK Mock and HOS Mock cells, as well as the differential signalling pathways 
induced by M-CSF or IL-34 in the HEK M-CSFR. To explore this hypothesis, HEK M-CSFR 
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cells were then treated with chondroitinases A, B, C solution (chABC) to abrogate the 
chondroitin sulfates (CS) present at the cell surface prior to study of the M-CSF- or IL-34-
induced signalling pathways. Consistent with the results presented in Figure 1B, the M-CSFR 
was less activated after addition of 50 ng/mL of IL-34 compared to stimulation with the same 
dose of M-CSF, as illustrated by the phosphorylation levels of tyrosines 546, 708 and 723 
(Figure 5A). Interestingly, the chABC treatment markedly increased the levels of M-CSFR 
phosphorylations induced by IL-34 as demonstrated by the phosphorylation levels of M-
CSFR, whereas the response induced by M-CSF remained unchanged (Figure 5A). Similar 
results were obtained for ERK1/2. Both cytokines were also pre-incubated with 1, 3 or 10 
µg/mL CS salts for 1h at 37°C prior to their addition to the HEK M-CSFR cells. The addition 
of CS did not modulate the M-CSF-induced signalling pathway (Figure 5B). On the contrary, 
pre-incubation of CS with IL-34 led to increased phosphorylation of the receptor tyrosines 
708 and 723 (Figure 5B). Overall, these data clearly demonstrated that CS strongly regulates 
the biological activities of IL-34. 
 
3.4. IL-34 binding to chondroitin sulfate is independent of the receptor protein tyrosine 
SKRVSKDWDVHȕȗ5373ȕȗ 
฀R฀P฀T฀Pȕ฀/ȗ฀,฀ ฀a proteoglycan mainly expressed in the central nervous system, was recently 
identified on the glioblastoma cell line U251 as another receptor for IL-34 through its CS 
chains, explaining the role of the cytokine in brain development >27@. We then analysed 
฀R฀P฀T฀Pȕ฀/ȗ฀ expression in THP-1, TF-฀1฀,฀ ฀H฀O฀S฀ ฀M฀o฀c฀k฀ ฀a฀n฀d฀ ฀H฀E฀ ฀ ฀M฀o฀c฀k฀ ฀c฀e฀ ฀ ฀s฀.฀ ฀T฀h฀e฀ ฀R฀P฀T฀Pȕ฀/ȗ฀ ฀w฀a฀s฀ ฀n฀o฀t฀ 
expressed at either the transcriptional or the protein levels in any of these cells in contrast to 
the U251 cells used as a positive control (Figure 6). IL-34 binding to the HEK Mock and 
HOS Mock cells was consequently ฀i฀n฀d฀e฀p฀e฀n฀d฀e฀n฀t฀ ฀o฀f฀ ฀R฀P฀T฀Pȕ฀/ȗ฀. 
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3.5. The IL-34-induced migration of myeloid cells is syndecan-1 dependent 
Within the proteoglycan families, the syndecans control a lot of biological functions, such as 
angiogenesis, cytokine bioavailability, cell adhesion/interactions, etc. To investigate the 
functional involvement of syndecans in IL-34 biology, syndecans 1, 2 and 4 were individually 
overexpressed in the HEK M-CSFR cells and the phosphorylation levels of the M-CSFR were 
then analysed in the presence of IL-34. The, overexpression of syndecan-1 in the HEK M-
CSFR cells exacerbated the cell response to IL-34 (Figure 7A,B). Indeed, this overexpression 
induced stronger activation of the M-CSFR when IL-34 was added compared to the effects in 
non-transfected cells (NT) or cells transfected with an empty plasmid (Mock), as shown by 
the increased phosphorylations of 708, 723 tyrosines (Figure 7B). In contrast, the 
overexpression of syndecan-2 or -4 did not have any impact on M-CSFR activation by IL-34 
(Supplementary data 4). The addition of a blocking syndecan-1 antibody reduced the IL-34-
induced M-CSFR activation as measured by the levels of 708, 723 tyrosine phosphorylations 
in cells overexpressing syndecan-1 (Figure 7C). Anti-syndecan-1 antibody did not modulate 
by itself the M-CSFR phosphorylation while it upmodulated IL-34 effects on M-CSFR 
activation in non transfected cells (Figure 7D). To confirm the involvement of syndecan-1 in 
the IL-34 induced signalization, the syndecan-1 gene expression was knocked down using 
specific human syndecan-1 siRNA. As expected, syndecan-1 siRNA significantly down 
regulated the expression of the membrane protein as observed by flow cytometry (Figure 8A). 
Similarly to the addition of a blocking syndecan-1 antibody, the knocking down of syndecan-
1 upregulated the M-CSFR phosphorylations (Figure 8B). Similar results were obtained for 
ERK1/2. We then compared the IL-34 dose response on the M-CSFR phosphorylations in 
HEK M-CSFR subpopulations expressing differentially syndecan-1 (Supplementary data 5).  
The data showed that IL-34-induced M-CSFR phosphorylations reached a plateau in the 
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presence of 25 ng/mL for pTyr-708 whereas no plateau was observed in cells expressing 
higher syndecan-1 expression even in the presence of 100 ng/mL of IL-34 (Supplementary 
data 5). These data demonstrated that syndecan-1 was able to modulate the biological 
activities of IL-34 through the M-CSFR. 
To elucidate the functional implication of the syndecan-1/IL-34 interactions, we first 
analysed the expression of syndecan-1 in various cell types (Figure 9A). Syndecan-1 appears 
highly expressed by several cell types with hematopoietic (THP-1), mesenchymal (HOS 
Mock) and epithelial (HEK Mock) origin in contrast to U937 and TF-1 cells. IL-34 
significantly increased the migration of THP-1 cells compared to the control (Figure 9B, p < 
0.001). This IL-34-induced THP-1 cell migration was abolished by the addition of a blocking 
anti-syndecan-1 antibody. We then investigated the expression of syndecan-1 by human 
monocytes/macrophages (Figure 9C). CD14+ cells expressed a very low level of syndecan-1 
and interestingly, when CD14+ cells were differentiated toward M2a macrophages (CD14low, 
CD200R+, CD86+), differentiated cells highly expressed the syndecan-1 (Figure 9C). We then 
investigated the effects IL-34 on syndecan-1 expressing M2a macrophages. IL-34 
significantly stimulated the migration of M2a macrophages (Figure 9C, p < 0.001).  Similarly 
to the THP-1 cells, the addition of a blocking anti-syndecan-1 antibody totally inhibited the 
IL-34-induced M2a macrophage migration. Anti-syndecan-1 antibody had no effect on cell 
proliferation or on IL-34-associated monocyte survival (data not shown). Overall, these 
investigations demonstrated that IL-34 induced the migration of myeloid cells in a syndecan-1 
dependent manner. 
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4. DISCUSSION 
IL-34 and M-฀C฀S฀F฀ ฀a฀r฀e฀ ฀c฀o฀n฀s฀i฀d฀e฀r฀e฀d฀ ฀a฀s฀ ฀“฀t฀w฀i฀n฀”฀ ฀c฀y฀t฀o฀k฀i฀n฀e฀s฀ ฀s฀h฀a฀r฀i฀n฀g฀ ฀c฀o฀ ฀ ฀o฀n฀ M-CSFR chains. 
However, while both cytokines have some functional overlaps, they also have specific 
activities, especially in the differentiation and activation of the monocyte/macrophage lineage, 
effects in favour of the existence of an additional, unknown receptor for IL-34 >13, 18-20@. 
Recently, Nandi et al. >27@ highlighted an alternative receptor for IL-34, the receptor protein 
฀t฀y฀r฀o฀s฀i฀n฀e฀ ฀p฀h฀o฀s฀p฀h฀a฀t฀a฀s฀e฀ ȕ฀/ȗ฀ ฀ ฀R฀P฀T฀Pȕ฀/ȗ฀ ฀, known to increase tyrosine phosphorylations of 
downstream prote฀i฀n฀s฀ ฀s฀u฀c฀h฀ ฀a฀s฀ ȕ-catenin, Src family kinases, focal adhesion kinase or Erk1/2. 
The present manuscript characterized a new binding mode for IL-34 to cells that express 
neither the M-CSFR, nor ฀t฀h฀e฀ ฀c฀h฀o฀n฀d฀r฀o฀i฀t฀i฀n฀ ฀s฀u฀ ฀f฀a฀t฀e฀ ฀p฀r฀o฀t฀e฀o฀g฀ ฀y฀c฀a฀n฀ ฀R฀P฀T฀Pȕ฀/ȗ฀.฀ ฀T฀h฀i฀s฀ ฀n฀e฀w฀ ฀I฀L-34 
binding is dependent on chondroitin sulfate chains, and syndecan-1 was identified as 
regulating the IL-34 activation levels of the M-CSFR. 
฀R฀P฀T฀Pȕ฀/ȗ฀ ฀i฀n฀t฀e฀r฀a฀c฀t฀s฀ ฀w฀i฀t฀h฀ ฀I฀L-34 through its chondroitin sulfate chains >27@. These 
authors demonstrated with enzymatic treatment and CS addition that chondroitin sulfate 
competed with IL-34 for binding ฀t฀o฀ ฀t฀h฀e฀ ฀e฀x฀t฀r฀a฀c฀e฀ ฀ ฀u฀ ฀a฀r฀ ฀d฀o฀ ฀a฀i฀n฀ ฀o฀f฀ ฀R฀P฀T฀Pȕ฀/ȗ฀,฀ ฀r฀e฀v฀e฀a฀ ฀i฀n฀g binding 
฀d฀e฀p฀e฀n฀d฀e฀n฀c฀e฀ ฀o฀n฀ ฀R฀P฀T฀Pȕ฀/ȗ฀ ฀c฀h฀o฀n฀d฀r฀o฀i฀t฀i฀n฀ ฀s฀u฀ ฀f฀a฀t฀e฀ ฀c฀h฀a฀i฀n฀s฀.฀ Like R P฀T฀Pȕ /ȗ ,  c h฀o฀n฀d฀r฀o฀i฀t฀i n฀ ฀s฀u฀ f a t e  
moieties seem to be a prerequisite for IL-34 binding to syndecan-฀1฀.฀ ฀R฀P฀T฀Pȕ฀/ȗ฀ ฀a฀n฀d฀ ฀s฀y฀n฀d฀e฀c฀a฀n-1 
are transmembrane proteoglycans with common features. Both proteins have 
glycosaminoglycans on their ectodomain, and their intracellular C-terminal moiety interacts 
with proteins containing the PDZ domain >28,29@. The polymorphism of glycosaminoglycans 
attached to the protein core of syndecan-1 is due to different post-translational modifications 
and is directly linked to tissue-specific functions >30@. Thus, the degree of glycosylation of the 
extracellular domain explains the versatility of the syndecan family. Syndecan-1 belongs to a 
proteoglycan family including four members: syndecan-1 mainly expressed in epithelial cells 
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>31@, syndecan-2 mainly present in mesenchymal cells >32@, syndecan-3 mostly found in 
neuronal and cartilage tissues >33@ and syndecan-4 which is ubiquitously expressed >34@. All 
members of this family have heparan sulphate chains but only syndecan-1 and syndecan-3 
display chondroitin sulfate chains on their protein core. Syndecan-4 has been also described, 
to a lesser extent, in a chondroitin sulphate-associated form >35@. Based on these data, IL-34 
binding to the various syndecans must be considered according to tissue context and, for 
instance, IL-34 binding to syndecan-3 must not be excluded in the brain, especially regarding 
the importance of both IL-34 and syndecan-3 in the neuronal environment. 
 Proteoglycans are commonly devoted to numerous biological functions >36@ and it is 
accepted that they control the activities of a lot of cytokines/growth factors with or without 
glycosaminoglycan binding domains such as the heparin binding domain. Thus, the various 
proteoglycans serve as a reservoir for cytokines/growth factors and also modulate their 
induced signalling pathways by acting directly on the cytokine/growth factors-receptor 
interaction or by the regulation of cytokine activation and/or turnover >37@. In light of these 
pleiotropic activities, glycosaminoglycans may be involved in the sequestration of IL-34 at 
the cell membrane as revealed by the chondroitinase treatment that increased the 
phosphorylation levels of the M-CSFR induced by IL-34 (Figure 5A). Abrogation of 
membrane chondroitin sulphate chains may then reduce the trapping of IL-34 in these chains 
and may facilitate IL-34 binding to the M-CSFR (Figure 10A, B). Similarly, the pre-
incubation of chondroitin sulphate chains with IL-34 upmodulated the signal transduction 
through the M-CSFR (Figure 5B). In this context, soluble chondroitin sulphate chains may act 
as competitors to their homologous membrane forms and may limit IL-34 sequestration at the 
cell surface, facilitating its interaction with the M-CSFR (Figure 10C). Interestingly, soluble 
chondroitin sulfates compete with IL-฀γ฀δ฀ ฀f฀o฀r฀ ฀b฀i฀n฀d฀i฀n฀g฀ ฀t฀o฀ ฀t฀h฀e฀ ฀e฀x฀t฀r฀a฀c฀e฀ ฀ ฀u฀ ฀a฀r฀ ฀d฀o฀ ฀a฀i฀n฀ ฀o฀f฀ ฀R฀P฀T฀Pȕ฀/ȗ 
>27@, in contrast to the extracellular domain of M-CSFR (present data).  
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The co-receptor functions of proteoglycans are well illustrated by their interaction with the 
fibroblast growth factor and its receptor (FGF/FGFR). The FGF was the first growth factor 
identified as being dependent on heparin/heparan sulphate chains for its binding to the FGFR. 
The ternary complex FGF/FGFR/proteoglycans formed directly modulates the signalling 
pathways induced by the growth factor >38@. The co-receptor role of glycosaminoglycans has 
then also been demonstrated for epidermal growth factor (EGF) >39@, hepatocyte growth 
factor (HGF) >40@, vascular endothelial growth factor (VEGF) >41@, Wnt factors >42@ or 
members of the transforming growth factors (TGFs) >43@. In these cases, syndecan-1, via its 
heparan sulphate chains, acts as a co-receptor for these growth factors. Our present results 
suggest that syndecan-1 may also act as a modulator for the tyrosine kinase M-CSFR, but 
through its chondroitin sulfate chains. Syndecan-1 exhibits a stimulatory or inhibitory role, 
probably depending on its expression level. Thus, a low/moderate level of syndecan-1 may 
sequestrate IL-34 at the cell surface through its chondroitin sulfate chains, limiting the 
interaction between IL-34 and the M-CSFR (Figure 8D). The overexpression of syndecan-1 
induced significant phosphorylation of the M-CSFR, reinforced by the presence of IL-34.  
Interestingly, the overexpression of syndecan-1 modulate the pTyr723 of the M-CSFR that 
was already associated with the activation of specific signaling pathways (PI3K, Rho 
GTPases, paxilline, SFKs/Pyk2, etc) involved in cell migration >2, 44@. In contrast, a blocking 
anti-syndecan-1 antibody significantly reduced the effects of IL-34. The enhanced activation 
by syndecan-1 may be explained by the membrane proximity between the M-CSFR and 
syndecan-1, the biodistribution of syndecan-1 at the cell membrane being directly related to 
its expression level. IL-34 stimulation did not induce detectable signalling pathways 
(Supplementary data 2) in MOCK cells expressing syndecan-1 but not the M-CSFR and the 
฀R฀P฀T฀Pȕ฀/ȗ. These findings strengthen the hypothesis of a regulator for syndecan-1 on IL-34 
signalling through the M-CSFR. Previous works have already identified specialised docking 
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sites for other receptors in the syndecan extracellular domains, such as integrins and tyrosine 
฀k฀i฀n฀a฀s฀e฀ ฀r฀e฀c฀e฀p฀t฀o฀r฀s฀.฀ ฀T฀h฀u฀s฀,฀ Į฀vȕ฀γ฀ ฀i฀n฀t฀e฀g฀r฀i฀n฀ ฀a฀n฀d฀ ฀i฀n฀s฀u฀ ฀i฀n-like growth factor 1 receptor (IGF1R) ar  
captured by syndecan-1 to form a ternary receptor mainly expressed on tumour cells and 
endothelial cells and involved in the angiogenesis process >45@. Further investigations will be 
necessary to investigate the potential role of syndecan-1 in the IL-34 trapping. 
 Syndecan-1 is implicated in the control of cellular chemoattraction. Indeed, membrane 
proteoglycans, including the syndecan family, are responsible of a chemotactif gradient on 
endothelial cells linked to the adherence and migration of numerous circulating cells such as 
neutrophils >46@. Syndecan-1 mediated the osteoprotegerin-induced chemotaxis in human 
peripheral blood monocytes and may control by this mechanism, the inflammatory process 
and the bone remodelling >47, 48@. Proteoglycans like syndecan-1 contributes to the control of 
the pathogenesis of osteolysis >49, 50@. Thus, tumor-derived syndecan-1 is associated a 
crosstalk with bone and an increase of osteoclastogenesis >49, 50@. By interacting with 
syndecan-1, IL-34 may have a double involvement in osteoclastogenesis, by inducing the 
migration of myeloid osteoclast precursors expressing syndecan-1 and by substituting for M-
CSF in RANKL-induced osteoclastogenesis >5@. In addition, IL-34 was already shown to 
drives in vitro the polarization of macrophages towards an M2 immunosuppressive phenotype 
and function [4]. Several reports have described the accumulation of TAMs in tissue during 
the tumour development and TAMs are considered to facilitate the metastatic process [51]. 
We showed that syndecan-1 controls the IL-34-induced M2 macrophage migration (Figure 9), 
which can be related to the role of IL-34 in the biology of M2 macrophages [4]. The increased 
expression of syndecan-1 by macrophages was already observed during the myeloid 
differentiation and during the inflammatory process [52, 53]. These authors found a link 
between macrophage motility and the expression level of syndecan-1.  
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Syndecan-1 can now be added to the list of key regulators of IL-34 activities in addition to M-
CSFR ฀a฀n฀d฀ ฀R฀P฀T฀Pȕ฀/ȗ, but not of M-CSF. By controlling IL-34 bioavailability, by modulating 
the recruitment of M-CSFR chains or the affinity of IL-34 to the receptor chains, and/or by 
acting as a regulator signalling of the M-CSFR, syndecan-1 may play a part in the role of IL-
34 in development >22@, bone >5@ and inflammatory diseases >6@. Consequently, new therapies 
targeting the IL-34/M-CSFR axis must now take into account the existence of other receptors 
for the cytokine. 
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FIGURE LEGENDS 
Figure 1: IL-34 and M-CSF differentially activate the M-CSFR. (A) M-CSFR expression 
on the cell membrane of human cells analysed by flow cytometry. TF-1: erythroblastic 
leukaemia cell line, HEK293: embryonary cell line; HOS: osteosarcoma cell line; HL-60, U-
937 and THP-1: myeloid leukaemic cell lines; HOS M-CSFR and HEK M-CSFR: HOS and 
HEK stably overexpressing M-CSFR; HOS Mock and HEK Mock: HOS and HEK cell lines 
transfected with the empty control vector. The isotype IgG1 was used as the control (in grey 
on the graphs). (B-E) Western blot investigations of tyrosine phosphorylation patterns of M-
CSFR and Erk1/2 phosphorylation after addition of 50, 100 or 200 ng/mL of IL-34 or M-CSF 
for 1 to 30 minutes, in HEK M-CSFR (B), HOS M-CSFR (C), TF-1 M-CSFR (D) and THP-1 
cells (E). All experiments were performed three times in independent conditions and a 
representative set of experiments is shown.   
 
Figure 2: IL-34 binds to M-CSFR with a high affinity. Increasing concentrations of 125I-
labelled IL-34 (IL-34*) or 125I-labelled M-CSF (M-CSF*) were incubated for 60 min at 4°C 
with 106 cells and bound and unbound fractions were determined as described in 
฀“฀E฀x฀p฀e฀r฀i฀ ฀e฀n฀t฀a฀ ฀ ฀P฀r฀o฀c฀e฀d฀u฀r฀e฀s฀”฀.฀ ฀C฀u฀r฀v฀e฀ ฀f฀i฀t฀t฀i฀n฀g฀ ฀w฀a฀s฀ ฀p฀e฀r฀f฀o฀r฀ ฀e฀d฀ ฀a฀s฀ ฀d฀e฀s฀c฀r฀i฀b฀ed  i n฀ t฀h e  “ M฀a฀t฀e฀r฀i฀a฀ ฀s  a n d  
฀M฀e฀t฀h฀o฀d฀s฀”฀ ฀s฀e฀c฀t฀i฀o฀n฀.฀ ฀T฀y฀p฀i฀c฀a฀ ฀ ฀c฀u฀r฀v฀e฀s฀ revealing a specific binding fraction of iodinated M-CSF on 
HEK M-CSFR cells (A) and of iodinated IL-34 on HEK M-CSFR (B) and THP-1 cells (C). 
Table summarizing the binding mode of M-CSF and IL-34 on the cells of interest (D). These 
experiments are representative of three times in independent conditions and a representative 
experiment is shown.   
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Figure 3: A new IL-34 binding independent of the M-CSFR. (A-B) Inhibition binding 
assays were carried out on HEK M-CSFR cells. After incubation of HEK M-CSFR cells with 
a saturating concentration of 125I-labelled IL-34 (IL-34*), increasing doses of unlabelled IL-
34 (A) or unlabelled M-CSF (B) were added to the cells. (C) Binding of 125I-labelled IL-34 
was assessed by Scatchard assay on HEK Mock cells which did not express the M-CSFR. (D) 
Competition assay of 125I-labelled IL-34 with unlabelled IL-34 was performed on HEK Mock 
cells. (E) Binding of HEK Mock cells on IL-34 or M-CSF spotted on a chip analysed by 
Surface Plasmon Resonance. All experiments were repeated three times in independent times. 
 
Figure 4: IL-34 binds to chondroitin sulfate but not to heparin/heparan sulfate chains. 
Interactions between IL-34 and glycosaminogycans were studied by surface plasmon 
resonance technology. Chondroitin sulfate A (A), chondroitin sulfate B (B), chondroitin 
sulfate C (C), or heparin (D) were injected on immobilised IL-34 using the parameters 
described in the ฀“฀M฀a฀t฀e฀r฀i฀a฀ ฀s฀ ฀a฀n฀d฀ ฀M฀e฀t฀h฀o฀d฀s฀”฀ ฀s฀e฀c฀t฀i฀o฀n฀. 
 
Figure 5: Chondroitin sulfate chains regulate the M-CSFR phosphorylations induced by 
IL-34. (A) HEK M-CSFR cells were treated with a mixture of chondroitinases A, B and C for 
90 min at 37°C, before addition of 50 ng/mL of M-CSF or IL-34 for 5 min. (B) HEK M-
CSFR cells were pre-incubated with 1, 3 or 10 µg/mL of chondroitin sulfate salts for 90 min 
at 37°C before addition of 50 ng/mL of M-CSF or IL-34 for 5 min. The phosphorylation 
patterns of the M-CSFR and ERK1/2 were assessed by Western blot. Total forms of M-CSFR, 
ERK1/2 ฀a฀n฀d฀ ȕ-actin were used as a loading control. Bar graphs show relative densitometric 
values of pTyr-723 normalized to the M-CSFR. Similar densitometric measurments were 
obtained for pTyr-746 or pTyr-708, normalized to the M-CSFR or to ȕ-actin. These 
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experiments were performed three times in independent conditions and a representative 
experiment is shown.   
 
Figure 6: HEK, HOS, THP-1 and TF-1 do not express the receptor protein tyrosine 
SKRVSKDWDVH5373ȕȟ ฀T฀h฀e฀ ฀e฀x฀p฀r฀e฀s฀s฀i฀o฀n฀ ฀o฀f฀ ฀t฀h฀e฀ ฀r฀e฀c฀e฀p฀t฀o฀r฀ ฀p฀r฀o฀t฀e฀i฀n฀ ฀t฀y฀r฀o฀s฀i฀n฀e฀ ฀p฀h฀o฀s฀p฀h฀a฀t฀a฀s฀e฀ ฀R฀P฀T฀Pȕ฀/ȟ฀ 
was assessed in the different cells used in the study both at the transcriptional level by 
quantitative RT-PCR (A), where expression was normalised against GAPDH mRNA levels, 
฀a฀n฀d฀ ฀a฀t฀ ฀t฀h฀e฀ ฀p฀r฀o฀t฀e฀i฀n฀ ฀ ฀e฀v฀e฀ ฀ ฀b฀y฀ ฀W฀e฀s฀t฀e฀r฀n฀ ฀ ฀ ฀o฀t฀,฀ ฀w฀h฀e฀r฀e฀ ȕ-actin was used as a loading control (B). 
These experiments were performed three times in independent conditions and a representative 
experiment is shown.   
 
Figure 7: Syndecan-1 modulates the M-CSFR phosphorylations induced by IL-34. HEK 
M-CSFR were transiently transfected with a plasmid-encoding human syndecan-1. (A) 
Syndecan-1 expression analysed by flow cytometry, 48 h after transient transfection. 
Syndecan-1 expression in Mock M-CSFR transfected with an empty vector of syndecan-1 
(empty histogram). Syndecan-1 overexpressing cells were stimulated with or without 50 
ng/mL of IL-34 for 5 min (B) in the presence or absence of 20 Pg/mL of syndecan-1 blocking 
antibody pre-incubated for 90 min (C). Similar experiments were performed on HEK M-
CSFR (non transfected for syndecan-1) with or without 100 ng/mL of IL-34 and/or 10 Pg/ml 
of anti-syndecan-1 antibody for 1 and 5 minutes (D). M-CSFR- and ERK1/2- 
phosphorylations were assessed by Western Blot, with the M-CSFR, ERK1/2 total forms of 
and GAPDH as a loading control. Bar graphs show relative densitometric values of pTyr-723 
and pTyr-708 normalized to the M-CSFR. These experiments were performed four times in 
independent conditions and a representative experiment is shown.   
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Figure 8: Syndecan-1 siRNA increases the phoshorylation M-CSFR induced  by IL-34.  
The syndecan-1 gene expression was knocked down using specific human syndecan-1 siRNA. 
(A) Syndecan-1 expression analysed by flow cytometry, 48 h after siRNA transfection. (B) 
Syndecan-1 knocked down cells were stimulated with or without 50 ng/mL of IL-34 for 5 min 
and M-CSFR-, ERK1/2-phosphorylations were assessed by Western Blot, with the total forms 
of M-CSFR and ERK1/2 as a loading control. Bar graphs show relative densitometric values 
of pTyr-723 normalized to the M-CSFR. Similar densitometric measurments were obtained 
for pTyr-708, normalized to the M-CSFR or to GAPDH. A representative experiment out of 
three independent experiments is shown.   
 
 
Figure 9: IL-34 increases the migration of myeloid cells through the syndecan-1. (A) 
Syndecan-1 expression by various myeloid, mesenchymal and epithelial cells analysed by 
flow cytometry. (B) THP-1 cells were preincubated with antibody to syndecan-1 (B-B4) or -4 
the correspond isotype matched IgG (IgG1) for 15 min. After washing twice, migration 
toward IL-34 (100 ng/mL) was tested for 6 hours. (C) M2a macrophage were obtained from 
CD14+ cells isolated from peripheral blood of healthy donors, cultured and differentiated in in 
RPMI  supplemented with 1% human serum, 1% penicillin/streptomycin, 50 ng/mL of IL-4 
for 5 days. The expression of syndecan-1 and their phenotype (CD14low, CD220R+, CD86+) 
were analysed by flow cytometry. M2a cells were collected by gentle scraping and their 
migration ability in the presence of IL-34 with or withoutan a blocking anti-syndecan-1 
antibody was assessed as described for the THP-1 cells.  The histograms show the percentage 
of the migrated cells compared to the IgG1 control. Graphs represent the mean ±SD of three 
independent experiments done in triplicate in each case. A Kruskal-Wallis test was performed 
฀f฀o฀ ฀ ฀o฀w฀e฀d฀ ฀b฀y฀ ฀a฀ ฀ ฀u฀n฀n฀’฀s฀ ฀p฀o฀s฀t-hoc between all the conditions. *** p < 0.001. 
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Figure 10: Schematic diagram hypothesizing the functional involvement of syndecan-1 
in the bioavailability and activities of IL-34. Potential interactions of IL-34 with M-CSFR, 
Syndecan-1 and chondroitin sulfates in control conditions (A), after chondroitinase ABC 
treatment (B), in the presence of exogenous chondroitin sulfate chains (C), and according to 
the levels of syndecan-1 expression (D). 
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Supplementary data 1: IL-34 and M-CSF differentially 
activate the M-CSFR. (A) Western blot analysis of tyrosine 
phosphorylation patterns of M-CSFR and Erk1/2 
phosphorylation in THP-1 cells after addition of increasing 
doses of M-CSF (1-30 ng/mL) for 5 minutes compared to 25 
ng/mL of IL-34. (B) Differential effects of M-CSF and IL-34 
on the phosphorylation of M-CSFR and Erk1/2 in 
myelomonocytic U937 cells.  
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Supplementary data 2: M-CSF did not bind HEK- and HOS-Mock cells licking the M-CSFR. 
Increasing concentrations of 125I-labelled M-CSF (M-CSF*) were incubated for 60 min at 4°C with 
106 cells and bound and unbound fractions were determined as described in « Experimental 
Procedures ». Specific binding fraction of iodinated cytokines. Curve fitting was performed as 
described in the « Materials and Methods » section. 
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Supplementary data 3: IL-34 does not induce detectable signaling 
pathways in absence of M-CSFR and !∀#∀∃%&∀ (A-B) HEK Mock and 
HOS Mock, which did not express neither the MCSF-R nor the #∃%∃&∋( , 
were stimulated with 200 ng/mL of IL-34 for 1, 5, 15, 30 or 60 min. (A) 
The total tyrosine phosphorylation pattern or (B) the phosphorylations of 
mTor, and Akt were analyzed by Western blot. β-actin, total mTor and total 
Akt were used as loading controls.!
!
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Supplementary data 4: Syndecan-2 and -4 have no effect on IL-34 
induced signaling pathways in contrast to Syndecan-1. HEK M-CSFR 
were transfected with the different forms of syndecan (1, 2 and 4). Fourty 
eight hours after transfection, cells were stimulated with 50 ng/mL of IL-34 
for 5 min, and M-CSFR tyrosine phosphorylations were assessed by Western 
blot. β-actin was used as a loading control. NT: Non-transfected cells; Mock: 
cells transfected with an empty plasmid; Syndecan-1, -2, -4: cells transfected 
with a plasmid coding for syndecan-1, -2 or -4. 
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